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ABSTRACT

Role of Cannabinoid Receptor Type 2 (CB2) in Late Stage Atherosclerosis
by
Makenzie L. Fulmer

Atherosclerosis is a chronic inflammatory disorder of medium and large vessels. Immune
signaling and dyslipidemia are two of several processes which influence lesion development in
atherosclerosis. Cannabinoids, such as those found in marijuana, exert their effects through two
cannabinoid receptors, CB1 and CB2. Recent studies using CB2 knockout mice and CB2selective ligands have shed light on a protective role of CB2 in early stages of atherosclerosis.
However, the role of CB2 in advanced stages of atherosclerosis remains unclear. To determine if
CB2 plays a role in advanced atherosclerotic lesion composition and progression, we
investigated the effects of systemic CB2 gene deletion on advanced atherogenesis in Ldlr-null
mice fed an atherogenic high fat diet (HFD) for 20-24 weeks. CB2 deficiency did not
significantly affect aortic root lesion area, however, CB2-/- mice had a significant increase (~1.9
fold) in the percentage of abdominal aorta surface occupied by lesion. CB2-/- mice also displayed
increased lesional macrophage content (~2.3 fold) and an unstable phenotype characterized by
significantly reduced smooth muscle cell/macrophage ratio and increased matrix
metalloproteinase-9 activity and mineralization. These results suggest that although CB2 does
not affect the size of atherosclerotic lesions, it does modulate the cellular and extracellular matrix
composition and promotes a stable phenotype. CB2+/+ and CB2-/- mice were also subjected to
treatments with either CB2-selective agonist, JWH-015, or antagonist, SR144528, over the last
four weeks of a 24 week atherogenic diet to identify the effects of CB2 stimulation on
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calcification of advanced lesions. No change was observed in body weight or cholesterol in
response to either treatment. SR144528 reduced triglycerides and mineralization of aortic root
lesions in CB2+/+ mice only. Aortic Runx2 and osteopontin were increased in response to JWH015 by a CB2-dependent mechanism. Administration of synthetic cannabinoids in an ex vivo
organ culture of CB2+/+ aortas revealed increased vascular calcification in response to CB2
blockade and decreased vascular calcification in response to CB2 activation. All together, these
results support a protective role for CB2 in late stages of atherosclerosis and suggests that drugs
targeting CB2 may be beneficial in the treatment of advanced atherosclerosis by affecting
osteogenic mechanisms implicated in the mineralization of lesions.
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CHAPTER 1
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death in the U.S., and has
accounted for more deaths than any other cause of death in the U.S. every year since 1919
(Benjamin et al. 2017). With advancements in medicine, deaths caused by CVD declined 28.8%
from 2003 to 2013, but despite this, CVD still accounts for 30.8% of all reported deaths in
America; over 2200 Americans die from CVD daily, averaging one death every 40 seconds
(Mozaffarian et al. 2016). The most prevalent form of CVD is coronary heart disease (CHD),
which alone causes 1 out of 7 deaths in the US. Approximately every 34 seconds, an American
suffers from a coronary event, with a death occurring every 1 minute and 24 seconds
(Mozaffarian et al. 2016). The underlying cause of CHD is atherosclerosis, a chronic
inflammatory disease characterized by the formation of cholesterol-rich plaques within the vessel
wall of large- and medium-sized arteries. Atherosclerosis is a multifactorial disease and several
genetic and environmental risk factors of atherosclerosis have been identified, such as
dyslipidemia, obesity, high-fat diet, diabetes, smoking, and hypertension (C.K. Glass and
Witztum 2001).
The wall of arteries is comprised of three distinct layers, shown in Figure 1.1. The intima
is the innermost layer and consists mostly of endothelial and smooth muscle cells (SMCs) with
macrophages present in irregular intervals. At the most luminal portion of the intima is a single
layer of endothelial cells, and the outermost portion consists of an elastic lamina (EL) that helps
to provide a connection between the intima and the middle layer. This middle layer, called the
media, consists of concentric sheets of SMCs that function in constriction and dilation of the
vessel and collagen, which also serves as a means to connect with the intima. A second EL is
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found at the outermost portion of the media and connects the media with the adventitia, the final
outer layer of the vessel that connects the vessel to surrounding tissue. The adventitia is mostly
made of connective tissue with unsystematically arranged collagen and elastin fibers.

endothelium

lumen

adventitia

lumen

media

intima

elastic
lamina

Figure 1.1 Cross-sectional diagram of artery layers. The vessel wall is composed of three distinct
layers known as the intima, media, and adventitia. Two elastic laminas serve to separate the
media from the inner and outer layers. A layer of endothelial cells separates the intima from the
lumen, which is where oxygenated blood flows.

Atherosclerotic plaques form in the intimal layer of arteries over several decades. These
plaques are generally divided in to three successive stages based on their morphological and
stabilizing characteristics: fatty streak, intermediate fibrous lesion, and advanced lesion (Figure
1.2). Fatty streaks (Figure 1.2b) are the first sign of atherogenesis that can be visualized
macroscopically on the intimal surface with the unaided eye and are present in the aorta of 99%
of children aged 2 to 15 years (Stary et al. 1994). This early, asymptomatic stage is characterized
by an influx of monocytes and low-density lipoprotein (LDL) particles that eventually give rise
to adjacent, stratified layers of macrophage-derived foam cells, creating a yellow streaking
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appearance on the intimal surface. Foam cells, considered the hallmark of atherosclerosis, are
retained in plaques and eventually contribute to disease progression by promoting insufficient
lipid metabolism and further compromising fundamental immune functions (Hansson and
Hermansson 2011). Lipids, which are mainly in the form of cholesteryl esters (CE) (Katz et al.
1976), are also contained within intimal SMCs at this stage but to a lesser degree than in
macrophages. Thinly dispersed lipid droplets are also found in the extracellular space in small
quantities, however most of the lipid seen during the fatty streak stage is within cells (Stary et al.
1994).
Fatty streaks can progress into intermediate fibrous lesions (Figure 1.2c) over several
years, a stage that serves as a morphological and chemical bridge between fatty streaks and
advanced lesions. On gross appearance, intermediate lesions resemble fatty streaks but are
widely different microscopically. These fibrous lesions contain increased amounts of
extracellular lipid droplets that bear more free cholesterol, fatty acid, and triglyceride
components than in fatty streaks (Stary et al. 1994). At this stage, SMCs deposit collagen and
other extracellular matrix (ECM) components in to the lesion to create a stabilizing fibrous cap.
A large lipid core is not well defined yet but the accumulation of several separate extracellular
lipid pools layered beneath the macrophages and foam cells disrupt coherent layers of intimal
SMCs and intercellular matrix proteoglycans and fibers (Stary et al. 1994). Like in the case of
fatty streaks, this second stage of atherosclerotic plaque development is not clinically significant.
However, culmination of this process over decades leads to the formation of large, structurally
unstable advanced lesions that give rise to incidences of myocardial infarction and stroke.
Advanced lesions, also known as atheromas (Figure 1.2d), are characterized by the presence of a
large necrotic core that is absent in preceding stages (Stary et al. 1995). Lesions contain an
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abundance of extracellular lipids forming lipid cores, pro-inflammatory cytokines, increased
amounts of cell death via apoptosis and necrosis, and enhanced collagen deposition (Ball et al.
1995; Kolodgie 2004). In more advanced lesions, mineralization and increased secretion of
proteolytic enzymes that diminish and damage collagen and elastin fibers in the internal EL,
eventually degrading the ECM, leading to lesional instability. Resulting consequences are plaque
fissuring and thrombolytic rupture, a predecessor to a series of detrimental coronary events.
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lumen

lumen

A. Normal artery

B. Fatty streak
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intima

intima
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lumen

media
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media
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lumen
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Figure 1.2 Stages of atherosclerotic progression. A) Non-diseased artery under normal conditions. The initial retention of modified LDL particles and circulating
monocytes in the subendothelial space marks the initiation of a fatty streak (B). Culmination of this process over several years results in an abundance of immune
cells and heightened secretion of proinflammatory cytokines. Smooth muscle cells begin to migrate toward the lumen in response to increased inflammatory
signaling in an attempt to stabilize the intermediate fibrous lesion (C). Increased amounts of cell death results in a large, unstable necrotic core underneath the
stabilizing fibrous cap. Proteolytic degradation of ECM components and mineralization of the fibrous cap occur in advanced lesions (D) and can lead to an
unstable phenotype that is prone to rupture and thrombolytic occlusion .
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While there is no cure for atherosclerosis, a common therapeutic strategy is to manipulate
serum lipid levels by the use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors (Buhaescu and Izzedine 2007). These drugs, commonly referred to as statins, reduce
cholesterol synthesis by inhibiting the rate limiting enzyme of the cholesterol synthesis pathway.
Reduction in cholesterol synthesis results in the upregulation of expression of LDL receptor by
hepatic cells, allowing for enhanced clearance of cholesterol-packed LDL from the circulation.
Statins also play a beneficial immunomodulatory role and have the ability to affect several
processes involved in the progression of atherosclerotic plaque formation. These include
enhancing endothelial cell differentiation, suppressing macrophage activation and endothelial
cell adhesion molecule expression, and inhibiting the migration and proliferation of vascular
smooth muscle cells (VSMCs) (Jones et al. 1998; Pitt et al. 1999; Vaughan et al. 2000; Bonetti et
al. 2003; Davignon and Ganz 2004; Ray and Cannon 2005). Despite the ability of statins to
reduce cardiovascular events in human and animal studies, this therapy has not been successful
in drastically decreasing mortality rates as 40% of patients with normal plasma lipid levels still
develop atherosclerotic plaques (Genest et al. 1991; Rubins et al. 1995; Yusuf et al. 2016). Also,
some patients are intolerant to statins. New therapies for managing atherosclerosis are needed,
independent of managing hypercholesterolemia.

Pathogenesis of Atherosclerosis

Under normal conditions, the monolayer of endothelial cells lining the intima comes in to
contact with flowing blood with high ability to resist adhesion of leukocytes and various other
immune cells. Unprovoked, spontaneous atherosclerosis is thought to occur through “response to
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injury,” a hypothesis proposed by Rudolph Virchow in 1856 that is still widely accepted today.
The basic premise of this hypothesis is that the formation of atherosclerotic lesions is a response
to an initial injury to arterial endothelial cells, which can be initiated by hyperglycemia,
increased levels of oxidized LDL (oxLDL) in circulation, sheer stress, and infectious pathogens.
After initial injury to the endothelial layer, an inflammatory response is initiated by lipids,
cellular debris, and inflammatory cells that become retained in the intima of the arterial wall.
Atherogenesis begins when various stimuli induce inflammatory cytokine release and
vascular endothelial expression of adhesion molecules. Elevated levels of LDL in plasma, which
can be attributed to high-fat diets (HFD) and genetic disorders, leads to retention of LDL in the
intima of the arterial wall where it becomes modified by several processes. One modification in
particular is the oxidation of LDL particles to become oxLDL, which stimulates the production
and secretion of pro-inflammatory cytokines, such as TNFα, IL-6, and IL-10 (Hamilton et al.
1990; Fong et al. 1991). This inflammatory response in turn initiates endothelial cell expression
of luminal adhesion molecules, such as intracellular adhesion molecule (ICAM)-1, vascular cell
adhesion molecule (VCAM)-1, and p-selectin (Dustin et al. 1986; Cybulsky and Gimbrone 1991;
Takahashi et al. 1996). Expression of these adhesion molecules allows for transmigration of
leukocytes, mainly blood monocytes, into the subendothelial space, where they differentiate into
macrophages and express scavenger receptors that bind and facilitate internalization of oxLDL
(Dhaliwal and Steinbrecher 1999). Receptor-mediated endocytosis of oxLDL by macrophages is
a continual process, and the cholesterol derived from the oxLDL particles is converted into
cholesteryl esters (CEs) by acyl coenzyme A: cholesterol acyltransferase (ACAT). CEs are
stored in lipid droplets in the cytoplasm of macrophages which give these cells a “foamy” or
“frothy” appearance, giving rise to the term “foam cell” which is the first hallmark of
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atherosclerosis (Moore et al. 2013).
Fatty streaks progress to intermediate plaques and the inflammatory process continues
with the recruitment of T cells (Jonasson et al. 1986) and B cells (Zhou and Hansson 1999). T
lymphocytes activate and perpetuate inflammation by secreting pro-inflammatory cytokines and
chemokines and recruiting additional immune cells. VSMCs are normally present in the medial
layer of the artery where they function as quiescent, contractile cells; however, they possess the
ability to transition to a proliferative phenotype when provoked following vascular injury,
playing in important role in the pathophysiology of atherosclerosis. Recruitment of immune cells
secreting pro-inflammatory cytokines and chemokines signals VSMCs to begin proliferating and
migrating from the medial layer of the artery towards the intima (Schönbeck et al. 2000). This
process marks the “fibrous plaque” stage of atherosclerotic lesion development, and the
migrating VSMCs attempt to stabilize the pro-inflammatory lipid core by depositing collagen
and other ECM components to create a fibrous cap. This mechanism can later be altered by the
pro-inflammatory cytokines and chemokines secreted by macrophages and T lymphocytes,
which can destabilize the ECM by impairing the synthesis of collagen by VSMCs and increasing
expression of MMPs (Hansson and Libby 2006).
As atherosclerotic lesions advance, they begin to undergo calcification by an active
process resembling embryonic osteogenic mechanisms and normal bone remodeling (Steitz et al.
2001; Trion and van der Laarse 2004; Bab et al. 2008). VSMCs transdifferentiate to an
osteoprogenitor cell type, and the presence of several transcription factors and other regulatory
proteins promote expression of osteogenic genes, allowing these cells to acquire a functional
osteoblast phenotype. Vascular calcium deposition reduces vessel elasticity and vessel wall
compliance (Trion and van der Laarse 2004; Sun et al. 2012) and is therefore a factor
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contributing to plaque instability. In addition to this, excess buildup of oxLDL and free
cholesterol in foam cells eventually initiates apoptotic cell death (Marchant et al. 1995). As the
number of apoptotic cells increases, inefficient clearance of these cells (efferocytosis) can result
in secondary necrosis. During secondary necrosis, lipids and other cellular debris are deposited
in the extracellular space (Tabas 2007), giving rise to a necrotic core. Stabilization of this lipidrich core by the fibrous cap is lost when inflammatory cells secrete MMPs which serve to
degrade ECM components, resulting in the weakening/thinning of the fibrous cap. When the
stability of atherosclerotic plaques in compromised, the risk of plaque rupture is very high. The
formation of a thrombus is initiated after a plaque ruptures; a result of pro-thrombotic materials
from the lesion being exposed to blood. Life threatening complications can arise from this
process, as thrombi can induce hypoxia by occlusion of the artery, leading to myocardial
infarction and stroke.
The Immune System in Atherosclerosis

The progression of atherosclerotic plaque development is influenced by both innate and
adaptive immune responses. The innate immune system is a subset of the overall immune system
that responds to pathogens in a non-specific but immediate fashion, and adaptive immunity is an
antigen-specific immune response that gives rise to immunological memory. Activation of the
innate immune system is important for eliciting an inflammatory response. Pattern recognition
receptors (PRRs) are necessary for detecting and clearing harmful materials. Cells of the innate
immune system are involved in several aspects of atherogenesis and express a diverse set of
PRRs that recognize both exogenous pathogenic components and endogenous products (Akira et
al. 2006). These PRRs can functionally be classified into two groups: endocytic receptors, which
facilitate the uptake of extracellular molecules and macromolecular complexes; and signaling
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receptors, which function to activate pro-inflammatory signaling pathways through upregulation
of pro-inflammatory genes. Examples of endocytic receptors are scavenger receptors, such as
SR-A (Lundberg and Hansson 2010) which is expressed on the surface of retained macrophages
and facilitates the clearance of oxLDL and formation of foam cells.
The major signaling PRRs are toll-like receptors (TLRs), which provide a link between
activation of innate immune responses through triggering acute inflammation and induction of
adaptive immune responses by activating co-stimulatory molecules necessary for cell-mediated
immunity. TLRs are type I transmembrane receptors and are ubiquitously expressed throughout
the body, with upregulated expression in atherosclerotic lesions on VSMCs, endothelial cells,
and macrophages (Edfeldt et al. 2002; Otsui et al. 2007). Stimulation of TLRs on macrophages
can result in release of proinflammatory cytokines TNFα, IL-1, and IL-6 as well as induction of
MMP expression. Recruitment and activation of T cells also occurs in response to TLR
stimulation, which potentiates the inflammatory process through production of more proinflammatory mediators, such as IFN𝛾 and TNFα, further stimulating SMCs, endothelial cells,
and macrophages within the lesion (Lundberg and Hansson 2010). Several TLRs exist and
collectively they recognize a diverse set of pathogen-associated molecular patterns (PAMPs) that
share commonality among many microorganisms (Akira et al. 2006). TLR2 and TLR4 have been
implicated in atherosclerosis. TLR4 is the receptor for lipopolysaccharide (LPS), a major
component in the cell wall of Gram negative bacteria, and systemic LPS administration in
hypercholesterolemic rabbits and atherogenic mice demonstrated a pro-atherosclerotic role (Lehr
et al. 2001; Ostos et al. 2002). TLR2 recognizes the largest variety of PAMPs on bacteria,
fungal, and viral products (Schwandner et al. 1999; Vabulas et al. 2001; Takeuchi et al. 2002;
Compton et al. 2003), and injection of a TLR2 ligand into hypercholesterolemic and atherogenic
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mice resulted in increased lesion severity (Mullick et al. 2005). In addition to these studies
showing that pathogenic products have the ability to promote atherosclerosis through TLR
signaling, several reports from epidemiological studies show an increased risk of atherosclerosis
associated with the following bacterial and viral pathogens: Chlamydia pneumoniae,
Helicobacter pylori, Porphyromonas gingivalis, Cytomegalovirus, Epstein-Barr virus, Human
Immunodeficiency virus, and certain strains of Herpes simplex virus, Influenza virus, and
hepatitis viruses (Michelsen et al. 2004; Desvarieux et al. 2005; Guan et al. 2008; Harskamp and
van Ginkel 2008).
Macrophages are key players in the initiation and progression of atherosclerotic plaques,
through their role in both cholesterol metabolism and innate immune response regulation.
Macrophages are phagocytic janitors that function to remove cellular debris and pathogenic
agents and secrete cytokines in order to regulate other immune processes. Most macrophages
present within atherosclerotic plaques originate from bone marrow-derived blood monocytes
(Mallat 2017), although recent evidence from lineage tracing studies has shown that many
macrophages transdifferentiate from SMCs within the plaque (Shankman et al. 2015). In the
beginning stages of atherogenesis, macrophages play a beneficial role through their ability to
ingest and clear accumulated lipoproteins from the subendothelial space. However, uptake of
modified lipoproteins is not well regulated and eventually macrophages become grossly
engorged with lipids, resulting in the formation of foam cells and dysregulation of lipid
metabolism (Moore et al. 2013). The LDL receptor is negatively regulated at the transcriptional
level by increases in cellular cholesterol. However, CD36, a type B scavenger receptor, is
positively regulated by oxLDL, and is one of the main receptors responsible for macrophage
uptake of modified lipoproteins (Van Berkel et al. 1998; de Winther et al. 2000; Nicholson and
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Hajjar 2004). These lipid-laden foam cells have diminished capacity to migrate out and
therefore accumulate, giving rise to a frothy appearance in the arterial wall characteristic of a
fatty streak. Foam cells impart a negative impact on disease progression two-fold: in beginning
stages, with compromised immune functions resulting in diminished capacity to migrate and
resolve inflammation; and in advanced stages, where they contribute to the inflammatory
response by secretion of pro-inflammatory cytokines and promote plaque instability by secretion
of matrix-degrading proteases (Randolph 2008; Moore et al. 2013).
Macrophages exhibit incredible plasticity and are able to change their physiological
function in response to their surrounding environment. The two most commonly seen and studied
macrophage phenotypes are classified as “pro-inflammatory” M1 and “anti-inflammatory” M2,
and switching to either phenotype occurs under the appropriate stimuli. The phenotype of a
macrophage has a large effect on its overall contribution to atherosclerotic plaque development.
M1 macrophage phenotype is induced by stimulation with Th1-secreted IFN𝛾 and LPS from
Gram-negative bacteria, and promotes inflammation by producing pro-inflammatory cytokines,
such as IL-1β, IL-12, and TNFα; and by attracting more monocytes through production of
monocyte chemoattractant protein (MCP)-1 (Tabas and Bornfeldt 2016). TLR4 signaling plays a
large role in the M1 response, as it can activate NFκB, ERK, p38 MAPK, and JNK signaling to
promote transcription of pro-inflammatory genes and enhance foam cell formation (Muslin
2008).
The M2 phenotype can be acquired in the presence of IL-4 and IL-13, two cytokines that
are largely produced by Th2 T cells. Ligand binding of IL-4 to the IL-4 receptor causes STAT6
activation, which can function to suppress TLR4 signaling. M2 macrophages produce antiinflammatory molecules, such as IL-10 and TGFβ (Tabas and Bornfeldt 2016), that lessen the
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pro-inflammatory response of Th1 cells and control cellular functions involved in tissue
remodeling and repair. M2 macrophages could be extremely beneficial in the regression of
atherosclerotic plaques, as they secrete factors that can promote collagen formation and can
function in the clearance of dying cells and debris within the lesion (Moore et al. 2013).
However, human atherosclerotic lesions show a Th1-dominant plaque environment, bearing
more IFN than IL-4 (Frostegård et al. 1999), resulting in more macrophages with the M1
phenotype. As these cells are not considered to have a pre-determined fate, it is likely they can
switch between phenotypes in the presence of an always changing microenvironment. Further,
the microenvironment of atherosclerotic plaques is highly variable depending on the location and
stage of development, which can affect the M1/M2 macrophage balance at any given moment.
TLR signaling also plays a role in antigen presentation by professional antigen presenting
cells (APCs), such as macrophages, contributing to activation and polarization of adaptive
immune processes. APCs present antigenic peptides to T cells to activate several different
immune functions depending on the class of T cell and type of antigen. The majority of T cells
are classified as either CD4+ or CD8+ T cells. CD4+ T cells are considered “helper” cells that
can illicit either a pro- or anti-inflammatory response depending on the cytokine environment.
CD8+ T cells are cytotoxic T cells that function to kill cells that are infected with intracellular
pathogens, such as viruses. Activated T cells are found in human and murine atherosclerotic
plaques (Hansson et al. 1989) and the magnitude of the pro-inflammatory response during
advanced atherosclerotic lesion development is largely regulated by T cells (Andersson et al.
2010). Although all subsets of T cells have been found in atherosclerotic plaques (Andersson et
al. 2010; Hansson and Hermansson 2011; Lahoute et al. 2011), several studies have shown more
CD4+ than CD8+ T cells (Stemme et al. 1995; de Boer et al. 1999; Andersson et al. 2010). Like
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macrophages, CD4+ T cells can acquire different phenotypes depending on the signals present in
the surrounding microenvironment. The most common subtypes present in atherosclerotic
lesions are Th1 and Th2, with Th1 cells being the most dominant T helper subtype (Laurat et al.
2001; Mallat et al. 2009).
T cells become activated within the atherosclerotic lesion when APCs present them
antigenic fragments, such as peptide fragments from modified LDL particles that mimic patterns
associated with pathogens, causing them to differentiate. Differentiation into a Th1 phenotype
occurs in the presence of macrophage-secreted IL-12 and IL-18 (Elhage et al. 2003), and Th1
cells are considered to be pro-atherogenic largely due to their secretion of IFN𝛾. A few studies
have shown that IFN𝛾 exacerbates plaque development, where injection of recombinant IFN𝛾
into ApoE-/- mice resulted in increased lesion size, and knockdown of IFN𝛾 in ApoE-/- mice
resulted in decreased lesion size (Whitman et al. 2000). Blockade of IL-12 and IL-18 signaling in
ApoE-/- mice also resulted in decreased plaque size (Mallat et al. 2001; Davenport and Tipping
2003) and increased collagen content (Mallat et al. 2001; Hauer et al. 2005), likely due to the lost
ability for Th1 differentiation and a subsequent decrease in IFN𝛾 secretion. The Th2 subset, like
the M2 macrophage phenotype, is characterized by anti-inflammatory actions; however, the role
of Th2 cells in the development of atherosclerotic lesions is controversial. Th2 differentiation is
stimulated in the presence of IL-4, a cytokine which opposes pro-atherogenic Th1 differentiation
and IFN𝛾 secretion. Whether or not Th2 cells are anti-atherogenic or not remains to be
elucidated, as IL-4 expression also stimulates some pro-atherogenic events, such as VCAM-1
and MMP expression and increased MCP-1 secretion (Barks et al. 1997; Y.W. Lee et al. 2001).
The role of CD8+ T cells in the progression of atherosclerosis is less clear than that of
CD4+ T cells. Knockdown of CD8+ in ApoE-/- mice resulted in no appreciable change in plaque
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burden (Elhage et al. 2004), however, CD8+ activation in ApoE-/- mice showed an increase in
plaque size (Olofsson et al. 2008). This data could indicate that the role of CD8+ T cells is minor
compared to the role of CD4+ cells under normal conditions, possibly bearing a more significant
role in the presence of a stimulus, such as an intracellular infection.
Atherosclerotic Plaque Instability
Atherosclerotic plaques, for the most part, remain “silent” throughout their progression,
bearing no complications. However, certain factors can provoke plaque rupture and endothelial
erosion, leading to ischemia and other life-threatening complications. Stable plaques contain a
fibrous cap made of a collagenous matrix, which serves to stabilize and protect the contents
within the lipid-rich core. It is when the surface continuity of the endothelium and fibrous cap
becomes compromised that complications can arise. Plaque rupture, also called fissuring, is seen
in about 75% of patients that present with acute coronary syndrome (Davies and Thomas 1984),
while over 25% of coronary thrombosis cases present with plaque surface erosion (Farb et al.
1996). Research on plaque disruption has been hindered due to lack of appropriate animal
models, as rodents rarely yield thrombolytic activity within plaques (Johnson and Jackson 2001;
Schwartz et al. 2007). Studies have shown, so far, that the actions of MMPs within the lesions, as
well as deposition of calcium, are among the processes contributing to unstable plaques and
plaque rupture.

Matrix Metalloproteinases (MMPs)
MMPs are endopeptidases that play an important role in controlling the composition of
the ECM. There are several classifications of these zinc-dependent proteases based on their
substrate specificity and function within the ECM: gelatinases, collagenases, matrilysins,

27

stromelysins, and other membrane type (MT) and unclassified MMPs (Snoek-van Beurden and
den Hoff 2005; Roy et al. 2006). At least twenty-three different MMPs have been identified in
humans (Raffetto and Khalil 2008), playing important roles in processes such as wound healing
and tissue repair (Johnson 2017 Sep 9). Some classes of MMPs are implicated in a range of
different pathologies, where they have increased expression and activity. Therapeutic targeting
of MMPs has been explored in the treatment of several maladies, including arthritis, cancer,
neurodegenerative diseases, and arthritis (Morgan et al. 2004; Fingleton 2007).
MMP activity is regulated at the level of gene transcription as well as by posttranslational mechanisms. These proteolytic enzymes are secreted in an inactive zymogen form
that requires subsequent stepwise activation, through a process of cleavage and conformational
change (Nagase et al. 2006). Multiple pathways for MMP activation exist within the
atherosclerotic plaque environment. Activation of several different MMPs occurs in the presence
of mast cell-secreted chymase and tryptase (Lees et al. 1994; Johnson et al. 1998), thrombin
(Galis et al. 1997), cathepsin G and K (Sukhova et al. 1998; Legedz et al. 2004), and members of
the plasmin system (Lijnen 2001), all of which are present in atherosclerotic plaques. Tight
regulation of MMPs is further seen with endogenous inhibitors, proteolysis, and internalization
and recycling (Nagase et al. 2006). The endogenous inhibitors, termed tissue inhibitors of
metalloproteinases (TIMPs), irreversibly bind to and inactive MMPs and are considered to be the
key regulators of MMPs under both normal and abnormal physiological conditions. Four TIMPs
have been identified, and all function to inhibit different MMP classes/molecules. A finely tuned
equilibrium of MMPs and TIMPs is needed in order to maintain a balance in ECM homeostasis.
It is known that plaque vulnerability is associated with increased inflammation,
proteolysis of structural ECM proteins, and reduced collagen content. High expression and
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disconcerted proteolytic activity of MMPs has been implicated in early and late stages of
atherogenesis. It is thought that in the early stages of plaque development, MMPs promote
migration and proliferation of immune cells and SMCs; in advanced plaques, excess
inflammation drives increased proteolytic activity of MMPs, leading to a weakened fibrous cap
and increased vulnerability to rupture (Wågsäter et al. 2011). In addition to inflammatory
cytokines functioning to provoke certain immune responses, molecules such as IL-1β, TNFα, and
IFN𝛾 also induce MMP expression by macrophages (Amento et al. 1991; Sarén et al. 1996).
The gelatinase class of MMPs, which includes MMP-2 and MMP-9, has been studied
extensively in the setting of cardiovascular diseases due to their regulatory function in VSMC
migration and proliferation (Johnson 2007). Clinical studies have shown that MMP-2 levels are
increased in patients suffering from acute myocardial infarction compared to healthy subjects,
and MMP-9 levels are increased in patients with more severe vessel disease compared to healthy
subject and subjects with less developed disease (Kai et al. 1998). Other studies have shown
increased MMP-9 expression in SMCs and macrophages within advanced plaques, as well as
increased MMP-9 proteolytic activity, compared to non-diseased vessels (Galis, Muszynski, et
al. 1994; Galis, Sukhova, et al. 1994). Although increased circulating MMP-9 levels are not a
clear indication for the presence of unstable plaques, several groups have shown the association
between acute coronary syndrome and heightened MMP-9 levels in circulation (Kai et al. 1998;
Inokubo et al. 2001). Most studies aimed at determining MMP relation to severity of
atherosclerotic disease has been conducted in later stages of atherogenesis from tissues collected
from human biopsies or mice genetically altered to overexpress or lack MMPs. One study used a
mouse model of atherosclerosis to determine expression and activity patterns of several MMPs
throughout the course of atherogenesis, and found that increases in MMP-2 and MMP-9
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expression and proteolytic activity specifically in atherosclerotic plaques are associated with the
progression of disease (Wågsäter et al. 2011).

Calcification
Mineralization of hard tissue, such as teeth and bones, occurs as a regulated process
under normal physiological conditions and is required in order for these tissues to properly serve
their purpose. It is only under pathological conditions that soft tissues become mineralized, and
these situations often give rise to consequences that are detrimental. Advanced atherosclerotic
plaques are among these scenarios of soft tissue mineralization that can result in adverse clinical
outcomes. Once thought to be a passive process, research has shed light on this ectopic
mineralization process, recognizing it as an active process resembling embryonic osteogenic
mechanisms and normal bone remodeling (Steitz et al. 2001; Trion and van der Laarse 2004; Bab
et al. 2008; Moore et al. 2013). Vascular calcium deposition reduces vessel elasticity and
augments plaque brittleness (Trion and van der Laarse 2004; Sun et al. 2012). Therefore,
mineralization of plaques affects overall vascular compliance and is a risk factor for myocardial
infarction and known to contribute substantially to the morbidity and mortality of cardiovascular
diseases (Detrano et al. 2008; Polonsky et al. 2010).
Current anti-atherosclerosis therapies, such as statins and beta-blockers, are aimed at
modulating the disease risk factors hypercholesterolemia and hypertension, respectively.
However, these therapies have not been successful in drastically decreasing mortality rates.
Therefore, development of new therapeutic approaches that are aimed at controlling or
decreasing calcification of atherosclerotic lesions could be beneficial in stabilizing late stage
atherosclerotic lesions and further decrease mortality rates.
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Lesion development involves many different cell types, such as monocytes/macrophages
and VSMC. Specifically, VSMCs are key contributors to lesion development through osteogenic
differentiation (Byon et al. 2008). Studies have provided much evidence to support the
hypothesis that vascular calcification mirrors regulatory processes seen in osteogenesis,
involving a balance between inhibitory and stimulatory molecules. Proliferation, extracellular
matrix maturation, and mineralization are the three major sequential phases of osteogenesis,
involving many key components that help facilitate the phase progressions (Vimalraj et al.
2015). Osteoblasts originate from mesenchymal stem cells and are matrix-producing cells that
are responsible for bone formation. Runt-related transcription factor 2 (Runx2) is a major
modulator in the process of osteogenesis and serves as a key transcription factor in the regulation
of osteoblast differentiation genes (Komori 2009; Vimalraj et al. 2015). Runx2 has been shown
to be essential in the early stages of osteogenic phenotype transition and phosphate-induced
matrix calcification of SMCs, which serve as a primary mediator in vascular calcification (Lin et
al. 2015). Downstream from Runx2 is a zinc-finger containing transcription factor, Osterix
(Osx), which is necessary for osteoblast differentiation and further bone formation (K.
Nakashima et al. 2002; K. Nakashima and de Crombrugghe 2003; C. Zhang 2012). Osx is
needed for the commitment of pre-osteoblasts to differentiate into mature, functioning
osteoblasts (C. Zhang 2012) and the specificity of Osx expression to osteoblasts is higher than
that of Runx2 expression (K. Nakashima and de Crombrugghe 2003). Several noncollagenous
bone proteins that are present during hard tissue calcification are also involved in the
calcification process of soft tissues, such as alkaline phosphatase (ALP) (Giachelli 1999),
osteocalcin (OCN) (Levy et al. 1983), and bone morphogenetic protein type 2 (BMP-2)
(Boström et al. 1993). Osteopontin (OPN) is another protein that plays a role in ectopic
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calcification of soft tissues. OPN is a ubiquitously expressed protein serving many different
functions depending on the environment, and specifically serves as a potent inhibitor of vascular
calcification (Lund et al. 2009).
While majority of cell types undergo terminal differentiation, the SMC phenotype bears
much plasticity. Characteristically, VSMCs exist as a mature contractile phenotype but have the
ability to differentiate into a synthetic fibroblastic phenotype in response to injury or disease
(Steitz et al. 2001). Osteoblastic transdifferentiation (OBT) of plaque VSMCs is a key step in the
atherosclerotic calcification process, sharing many features to the synthetic VSMC phenotype.
During this transition, VSMCs dedifferentiate into a mesenchymal stem cell that serves as a
precursor to osteochondrogenic cell lineages (Figure 1.3).
Under appropriate stimuli, VSMC begin acquiring an osteoblast-like phenotype,
characterized by the loss of smooth muscle (SM)22α and SM α-actin markers and the
upregulation of Runx2 (Steitz et al. 2001). Increased expression of Runx2 can directly stimulate
the transcription of type I collagen (ColI) (Franceschi et al. 2003), which is necessary before
osteoblasts can differentiate and express other osteogenic genes, like OCN and ALP (Franceschi
1999). While increased Runx2 is necessary during the beginning stages of OBT, its presence can
serve to inhibit maturation of pre-osteoblasts in later stages (McGee-Lawrence et al. 2014). Once
these cells have committed to the osteoblast lineage and adopt a pre-osteoblast phenotype, only
Osx is required for maturation into a calcifying cell. Presence of Runx2 or OPN at this stage can
halt the calcification process (Figure 1.3).
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Figure 1.3 Vascular smooth muscle cell (VSMC) osteoblastic transdifferentiation (OBT).
VSMCs dedifferentiate into a mesenchymal stem cell (MSC), a precursor to osteoblasts. Runx2
is necessary for the commitment of MSCs to the osteoblast lineage, but negatively regulates the
maturation of immature osteoblasts into mineralizing cells. Osterix (OSX) is necessary for final
stages of osteoblast maturation. Osteopontin (OPN) transcription is regulated by Runx2 and
functions as a negative regulator of ectopic calcification.

A homeostatic balance between osteoblasts and osteoclasts is essential for normal bone
remodeling. Opposite from osteoblasts, osteoclasts are large, multinucleated cells that function to
absorb bone tissue during repair and remodeling. Osteoclasts can differentiate from
monocytes/macrophages and share many signaling molecules and regulatory mechanisms with
immune cells (Takayanagi 2007). The most important cytokine involved in osteoclast
differentiation and activation is receptor activator of nuclear factor 𝜅-B ligand (RANKL).
RANKL is expressed by mesenchymally-derived cells, such as osteoblasts, and proteolytic
cleavage of this membrane-anchored molecule allows for soluble RANKL to bind to RANK to
initiate osteoclastogenesis (T. Nakashima et al. 2000). Differentiation and activation of
osteoclasts can be inhibited by osteoprotegerin (OPG), a soluble decoy receptor for RANKL
expressed by mesenchymal cells. The presence of OPG inhibits RANKL binding to RANK on
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osteoclasts, resulting in diminished NFkB activation. Evidence from several studies has
demonstrated an essential role for the RANKL/RANK/OPG system in maintaining normal bone
homeostasis, and mutations in these genes can result in bone disorders, such as autosomal
recessive osteopetrosis in the case of mutated RANKL (T. Nakashima and Takayanagi 2009).
Exact mechanisms of plaque calcification remain to be elucidated, but evidence is accumulating
that shows an association between increased inflammation and uncontrolled biomineralization of
plaques.

Mouse Models of Atherosclerosis
The most common way to study atherosclerosis in vivo is by use of mice that have
genetic modifications resulting in hypercholesterolemia. Wild-type mice are resistant to
atherosclerosis and have high levels of high-density lipoproteins (HDL) in plasma. Mice are
beneficial due to their short breeding times and production of large litters, ease of achieving
genetic modifications, and low cost of maintenance compared to other animal models. While
almost ten murine models of atherosclerosis exist, the most widely used strains are knockouts
that are deficient in either the low-density lipoprotein receptor (Ldlr-/-) or apolipoprotein-E
(ApoE-/-), the first gene-knockout mice to develop advanced atherosclerosis coupled with severe
hypercholesterolemia.
ApoE, a major component of very low-density lipoproteins (VLDL), is synthesized by
the liver and macrophages and functions to package cholesterol for lipoprotein transport, playing
an atheroprotective role. Ldlr expression is mostly on hepatocytes (Traber and Kayden 1980;
Jaakkola et al. 1989) and functions to facilitate lipoprotein clearance by binding apoB100 and
ApoE. Familial hypercholesterolemia is caused by mutations in the LDLR gene resulting in
inefficient clearance of lipoproteins (Goldstein et al. 1983; Tolleshaug et al. 1983). The major
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differences between these two mice strains are the induction of atherosclerotic disease and the
pace of progression (Maganto Garcia et al. 2012). ApoE-/- mice are severely
hypercholesterolemic from birth while Ldlr-/- mice only have mildly elevated circulating
cholesterol levels. Differences are also seen in the lipoprotein profiles of these mice, where
ApoE-null mice have more cholesterol contained in VLDL, and Ldlr-null mice have more
cholesterol contained in LDL particles which more closely resembles the lipoprotein profile of
humans. On a standard chow diet, ApoE-/- mice can develop quantifiable lesions within six
weeks, and lesion formation and progression can be exacerbated with the addition of a
cholesterol-rich atherogenic diet, which is a common practice. On the other hand, Ldlr-/- mice
will not develop quantifiable lesions for at least six months on a standard diet, as the extent of
disease is mostly correlated with the degree of hypercholesterolemia. Most studies utilizing Ldlr/-

mice thereby are conducted by feeding an atherogenic diet to induce hypercholesterolemia

required for the formation of atherosclerotic lesions. A typical atherogenic diet used with both of
these mice models is the “Western” diet. Also referred to as the “meat-sweet diet” or “standard
American diet”, the Western diet mimics a typical diet seen in modern Western society
consisting of high amounts of saturated fat and trans-fatty acids (Odermatt 2011). A positive
correlation exists between higher incidence of cardiovascular complications and obesity with a
western-style dietary pattern (Kant 2004; Zarraga and Schwarz 2006), making this diet
appropriate for diet-induced hypercholesterolemia and atherogenesis with murine models of
atherosclerosis. The typical Western diet fed to these mice usually contains 21% butterfat and
0.2% cholesterol, although cholesterol levels may vary (Merat et al. 1999).
While these mice are cost effective and beneficial for studying atherosclerosis, there are a
few drawbacks seen with use of these mouse models. For instance, atherogenic diets can cause
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potential inflammatory effects that are not related to the actual progression of atherosclerosis,
and mice lack late stage plaque rupture, a complication commonly seen in humans. Further,
similar treatments can result in varying effects between the different mouse models used, and
this must be taken into consideration when selecting a model, as further genetic manipulation or
treatments can be affected by the preceding genetic and physiological background.
The Endocannabinoid System

The medicinal usage of Cannabis for the treatment of a wide variety of human ailments,
from headaches to sexually transmitted diseases to cancers, have been documented as far back as
the 15th century (Grotenhermen and Müller-Vahl 2012; Borgelt et al. 2013). The medicinal
properties of Cannabis are attributable to the unique aryl-substituted meroterpenoid compounds,
called cannabinoids, produced in the Cannabis genera of plants (Ashton 2001). Over 50 years
ago researchers at the Hebrew University of Jerusalem isolated and characterized the first
cannabinoid, (-)delta-9-tetrahydrocannabinol (THC), the main psychoactive component of
marijuana (Gaoni and Mechoulam 1964; Gaoni and Mechoulam 2002) . Since then, more than
100 different cannabinoid compounds have been identified in Cannabis, however, only a few of
these have been extensively studied (Aizpurua-Olaizola et al. 2016). For the next nearly thirty
years, how THC (and other cannabinoids) produced specific biological effects was unknown,
with most speculating that the hydrophobic nature of cannabinoids resulted in nonspecific
interactions with cell membranes. However, in the late 1980s evidence accumulated supporting a
specific signal transduction mechanism for cannabinoids and in the early 1990s two membranebound cannabinoid receptors were identified, cloned and characterized (Matsuda et al. 1990;
Munro et al. 1993). These cannabinoid receptors, and their later discovered endogenous ligands
(endocannabinoids) and metabolic enzymes, are collectively termed the endocannabinoid system
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(ECS) (Fig. 1.4). Over the past 30 years, preclinical studies have shown that the ECS functions
in a wide variety of physiological and pathological processes; with alterations in both the levels
of CB1 and CB2 receptor expression and levels of their endogenous ligands being associated
with several human diseases including neurological conditions, metabolic disorders,
cardiovascular diseases, as well as some cancers (Pacher et al. 2006; Pacher and Kunos 2013).
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Figure 1.4 The Endocannabinoid System (ECS). The ECS consists of two known receptors, CB1
and CB2, the endogenous ligands for these receptors (endocannabinoids), and the metabolic
enzymes involved in the synthesis and degradation of endocannabinoids. Endocannabinoids are
synthesized intracellularly and transported to the extracellular space where they bind to and
mediate signaling of the cannabinoid receptors.

Cannabinoid receptors
The first cannabinoid receptor identified, and later termed cannabinoid receptor type 1
(CB1), was independently cloned from rat and human brain cDNA libraries in 1990 (Gérard et
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al. 1990; Matsuda et al. 1990). Shortly thereafter, another cannabinoid receptor, termed
cannabinoid receptor type 2 (CB2), was cloned from HL60 cells, a human promyelocytic
leukemia cell line (Munro et al. 1993). CB1 and CB2 are products of distinct intronless genes
(CNR1 and CNR2, respectively) with CNR1 located on chromosome 6 in humans and
chromosome 4 in mice, and CNR2 located on chromosome 1 in humans and chromosome 4 in
mice. Both are members of the G-protein coupled receptors (GPCR) superfamily of cell
membrane receptors, containing seven transmembrane spanning domains separated by three
intracellular and three extracellular loops, a glycosylated extracellular N-terminus and an
intracellular C-terminus. Overall, human CB1 and CB2 share 44% amino acid similarity, with
68% homology within their transmembrane domains (Munro et al. 1993). Both receptors are
relatively highly conserved among mammals, for example CB2 sequence identity between
humans and rodents is ≥80%.
CB1 is abundantly expressed by neurons in the brain, most notably in the cerebral cortex,
basal ganglia, cerebellum, and hippocampus (Matsuda et al. 1990) where it is responsible for the
psychotropic effects of THC. CB1 is also expressed at lower levels in parts of the peripheral and
autonomic nervous system, as well as several tissues, including heart, lung, thymus, spleen, and
reproductive organs (Howlett et al. 2002; Bonz et al. 2003; Quarta et al. 2010). Expression of
CB1 has also been noted in immune cells, but at levels up to 100 fold lower than CB2 (Galiègue,
Mary, Marchand, Dussossoy, Carrière, Carayon, Bouaboula, SHIRE, et al. 1995). Although CB1
has been shown to play a role in modulating nociception, anxiety, energy metabolism and
lipogenesis, the potential for undesirable psychotropic effects has greatly hindered the
development of CB1-targeted pharmacologic therapies. For example, Rimonabant, a CB1selective antagonist developed by Sanofi-Aventis was demonstrated to reduce body weight and
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improve cardiovascular risk factors in humans and was given approval as an anti-obesity drug in
Europe in 2006 (Ravinet Trillou et al. 2003) (Mølhøj et al. 2010) (Després et al. 2005) (PiSunyer et al. 2006) (Van Gaal et al. 2005; Scheen and Van Gaal 2007). However, in 2008,
despite producing beneficial metabolic and cardiovascular effects, Rimonabant was withdrawn
from use in Europe due to adverse psychiatric side effects resulting from its activity in the CNS.
Rimonabant never gained approval from the FDA for use in the United States.
CB2 is mainly expressed by cells of the peripheral immune system where it mediates the
immunosuppressive effects of THC (Buckley et al. 2000; Eisenstein et al. 2007). Expression of
CB2 by immune cells varies (B lymphocytes> natural killer cells >macrophages, ≥monocytes ≥
neutrophils>T-cells) (Bouaboula et al. 1993; Munro et al. 1993; Galiègue, Mary, Marchand,
Dussossoy, Carrière, Carayon, Bouaboula, Shire, et al. 1995) and can be greatly affected by the
differentiation and activation state of the cell. For example, macrophages activated by
thioglycollate or IFN-γ express significantly more CB2 than unstimulated macrophages (Carlisle
et al. 2002). Generally, the expression of CB2 by non-immune cells is very low, but it has been
observed in several other cell types including osteogenic cells (Ofek et al. 2006), cardiomyocytes
(Bouchard et al. 2003), fibroblasts (Defer et al. 2009), endothelial cells (Ronco et al. 2007), and
VSMCs (Rajesh et al. 2008). Expression of CB2 in the CNS is controversial, as some studies
failed to detect CB2 mRNA in neurons by Northern blotting and in situ hybridization analysis
(Munro et al. 1993), while others found very low levels using quantitative PCR analysis (Maresz
et al. 2005). However, expression by hematopoietic-derived microglial cells, rather than neurons,
could not be ruled out (Maresz et al. 2005). A number of immunostaining studies have reported
low levels of CB2 expression in some areas of the brain (Van Sickle et al. 2005; Gong et al.
2006; Brusco et al. 2008; Callén et al. 2012; Kim and Li 2015), however, inconsistent results
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obtained with CB2 antibodies from different sources, as well as similar staining patterns
produced in mice genetically altered to lack CB2, makes interpretation of these immunostaining
experiments tenuous (Buckley et al. 2000; Baek et al. 2013). Validation of CB2 expression in
the CNS awaits more specific CB2 antibodies or implementation of other methods specific for
CB2 detection.
CB1 and CB2 were initially characterized as GPCR that couple primarily to pertussis
toxin sensitive Gi/o signal transduction proteins and, when activated, inhibit adenylate cyclase to
reduce intracellular cyclic AMP levels and modulate downstream cascades under the control of
protein kinase A (PKA). In addition to affecting cAMP/PKA and Ca2+ signaling, emerging
evidence indicates that cannabinoid receptors modulate multiple diverse signaling networks in a
variety of cell types, including the mitogen-activated protein kinases/extracellular signal–
regulated kinases (MAPK/ERK1/2), phosphoinositide-3-kinase–protein kinase B/Akt (PI3KPKB/Akt), phospholipase C, Janus kinase and Signal Transducer and Activator of Transcription
(JAK/STAT) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB)
pathways (Bouaboula et al. 1995; Bouaboula et al. 1996; Howlett 2005; Demuth and Molleman
2006).

Endocannabinoids
The cloning of CB1 and CB2 led to the discovery of endogenous cannabinoids, or
endocannabinoids (ECs), that act as ligands of these receptors, including Narachidonoylethanolamide (anandamide, AEA) (Devane et al. 1992), 2-arachidonoylglycerol (2AG) (Mechoulam et al. 1995; Sugiura et al. 1995), 2-arachidonyl glyceryl ether (2-AGE, noladin
ether) (Hanus et al. 2001), O-arachidonoyl-ethanolamine (OAE, virodhamine) (Porter et al.
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2002), and N-arachidonoyl dopamine (NADA) (Bisogno et al. 2000). These ECs are bioactive
lipid mediators that share a common backbone structure resulting from their synthesis from
membrane phospholipid precursors containing arachidonic acid. Of these, AEA and 2-AG are
considered to be the primary endogenous activators of CB1 and CB2 and are the best studied,
while the functions and physiological roles of the others are unclear and require further
investigation. AEA is a partial agonist of CB1 (Mackie et al. 1993; Atmaram D Khanolkar et al.
1996; Felder et al. 1999; M. Glass and Northup 1999) and a weak partial agonist of CB2
(Gonsiorek et al. 2000). 2-AG is a full agonist of both CB1 and CB2 (Mechoulam et al. 1995;
Gonsiorek et al. 2000). Compared to most tissues, AEA and 2-AG levels are significantly higher
in brain, however, detectable levels of both have been found in numerous other mammalian
organ systems, including bone marrow, kidney, liver, spleen, plasma, adipose, and gut, with 2AG being more abundant than AEA in most tissues (Mechoulam et al. 1998).

Metabolism of Endocannabinoids
Generation of AEA and 2-AG has been shown for only a limited number of cell types,
most notably in stimulated neurons, platelets and macrophages (Sugiura et al. 2002). Both AEA
and 2-AG are synthesized and released only on demand after an appropriate stimulation and, in
most cases, uptake and intracellular degradation rapidly terminates their activity. Synthesis of
AEA occurs as a two-step process, beginning with the formation of N-arachidonoyl
phosphatidylethanolamine (NAPE) from phosphatidylethanolamine (Sugiura et al. 1996)
followed by the cleavage of NAPE by NAPE phospholipase D to generate AEA (Basavarajappa
2007). Like AEA, 2-AG is also synthesized in a two-step process, where diacylglycerol (DAG)
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is generated by phospholipid C-regulated hydrolysis of membrane phospholipids and converted
to 2-AG by DAG lipase (Basavarajappa 2007).
Two enzymes are primarily responsible for the rapid turnover of ECs; fatty acid amide
hydrolase (FAAH) which metabolizes AEA to free arachidonic acid and ethanolamine, and
monoacylglycerol lipase (MAGL) which metabolizes 2-AG to free arachidonic acid and glycerol
(Deutsch and Chin 1993; Cravatt et al. 1996; Maccarrone et al. 1998; Dinh et al. 2002; Saario et
al. 2004). FAAH has also been reported to metabolize 2-AG, at least under some conditions
(Goparaju et al. 1999). AEA and 2-AG metabolism is summarized in Figure 1.5. Transport
mechanisms for uptake and reuptake of AEA and 2-AG are not completely understood, but in
addition to their lipophilic nature that allows them to passively diffuse across cell membranes,
facilitated diffusion by protein transporter mechanisms is likely to also occur (Basavarajappa
2007).
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Figure 1.5 Metabolism of 2-AG and AEA. Synthesis of both 2-AG and AEA occurs as a twostep process, and degradation of both yields arachidonic acid (AA).

CB2-deficient mouse models
The use of mice genetically altered to lack CB2 expression has enabled investigators to
examine how CB2 specifically functions in various disease states, giving rise to potential novel
CB2-directed therapies aimed at reducing the burden of disease. The first CB2 knockout mouse
(Cnr2tmZim) was generated in 2000 in chimeras of 129 (H-2b) and C57BL/6 (H2-b) mice by
inactivation of the CNR2 gene using homologous recombination to eliminate part of the
intracellular loop 3, transmembrane domains 6 and 7, and the carboxyl extremity of the receptor
(Buckley et al. 2000). In this model of CB2 inactivation, CB1 expression and function is
unaltered and there are no morphological differences between these mice and their wild type
counterparts. At a cellular level, one study found that CB2-null mice present with abnormal
development of certain subsets of T and B cells (Ziring et al. 2006), however, spontaneous
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development of any observable immune disorder has never been noted in these mice. It should be
noted that strain-specific genetic effects can still be observed even after extensive backcrossing.
WT mice should be obtained from the same breeder in order to identify whether an experimental
outcome is CB2-dependent or a genetic effect specific to the strain.
A second CB2 knockout mouse was generated by Deltagen (Cnr2tm1Dgen) and is available
from Jackson Labs (Bar Harbor, ME). Inactivation of CNR2 was achieved by homologous
recombination in E14 stem cells from129P2/OlaHsd mice followed by at least 5 generations of
backcrossing with a mixed C57BL/6J;C57BL/6N background. In a study comparing Cnr2tmZim
and Cnr2tm1Dgen, it was found that GRP55 signaling was impaired only in Cnr2tmZim mice (Sisay
et al. 2013). Cnr2tmZim mice still have the ability to generate a truncated CB2 message due to the
presence of an intact CNR2 promotor and N terminus, and it is possible that GRP55 signaling is
affected by a dysfunctional CB2 message or signal (Buckley et al. 2000; Sisay et al. 2013). Other
differences seen between the two CB2 knockout models may reflect differences in their genetic
backgrounds. Despite this, both CB2-deficient mice models are widely accepted and used; the
use of CB2-null mice has proven to be an instrumental tool in cannabinoid research and defining
a role for CB2 in various inflammatory disease models.

ECS and Atherosclerosis
Clinical and experimental data has emerged indicating that local and systemic
fluctuations in expression of ECS components is strongly associated with atherosclerosis,
suggesting that alterations in EC levels or CB receptor expression may represent biomarkers of
ongoing vascular disease. Increased systemic ECs are present in patients with coronary artery
disease (Sugamura et al. 2009), and CB2 expression is upregulated in activated macrophages
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(Carlisle et al. 2002; Rajesh et al. 2008) and has been detected within atherosclerotic plaques of
both human coronary arteries and aortas of mice, but is not found in non-diseased vessels
(Steffens, Veillard, Arnaud, Pelli, Burger, Staub, Zimmer, Frossard, and Mach 2005a;
Montecucco et al. 2012).
The first experimental evidence indicating a role for CB2 in atherosclerosis came from a
study by Steffens et al. in 2005, demonstrating that ApoE-/- mice given a low oral dose of THC
developed significantly smaller plaques with fewer macrophages than untreated control mice
(Steffens, Veillard, Arnaud, Pelli, Burger, Staub, Zimmer, Frossard, and Mach 2005b). Coadministration of SR144528, a CB2-selective antagonist, reversed the effects of THC on lesion
progression, providing strong evidence that the effects of THC on atherosclerosis were mediated
by CB2. It should be noted that the dose of THC used in this study was below that at which
psychotropic effects are produced, a major concern for the development of cannabinoid-based
therapies. Similar effects were seen with WIN55,212-2, a potent synthetic CB receptor agonist
that produces similar effects as those seen with THC. In one study by our laboratory, two weeks
of daily intraperitoneal injections of WIN55,212-2 in early atherogenic Ldlr-/-CB2-/- mice
resulted in reduced plasma triglycerides and decreased macrophage accumulation in aortic root
plaques (Netherland-Van Dyke et al. 2015). These results were consistent with our previous
findings that systemic CB2-deletion resulted in increased macrophage infiltration in
hyperlipidemic Ldlr-null mice (Netherland et al. 2010). Administration of WIN55,212-2 in the
ApoE-/- mouse model not only reduced atherosclerotic plaque size and macrophage content, but
also decreased expression of VCAM-1 and reduced expression of pro-inflammatory mediators,
including blocking NF𝜅B activation by oxLDL (Zhao, Y. Liu, et al. 2010; Zhao, Yuan, Y. Liu,
Xue, Tian, W. Liu, W. Zhang, Shen, Xu, Liang, and Chen 2010a). These effects were blunted in
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the presence of a CB2-selective antagonist AM630, providing evidence of these results also
being CB2-dependent. Since VCAM-1 is a necessary component of transendothelial migration of
blood monocytes and other components of the immune system, a reduction in its expression on
the endothelium could hinder the progression of plaque size by limiting the rate at which
monocytes migrate into the subendothelial space. Several in vitro studies have also confirmed the
role of CB2 in macrophage infiltration and expression of cell adhesion molecules.
Administration of both HU-308 and JWH-133 blunted TNFα-induced VCAM-1 and ICAM-1
expression on human coronary artery endothelial cells (HCAECs) (Rajesh et al. 2007), and this
effect was also seen with WIN55,212-2 administration in human umbilical vein endothelial cells
(HUVECs) (Zhao, Y. Liu, et al. 2010). Both studies also showed a reduction in adhesion of
monocytes, and the effects on both endothelial cells and monocytes were all blunted in the
presence of a CB2-selective antagonist. Steffens et. al. also provided evidence for low doses of
THC inhibiting macrophage migration in response to MCP-1, which was blocked by SR144528
(Steffens, Veillard, Arnaud, Pelli, Burger, Staub, Zimmer, Frossard, and Mach 2005b). Further,
the effects of THC were not seen in macrophages isolated from CB2-null mice.
In addition to affecting migration of macrophages, CB2 activation may also affect
migration of other cell types in atherosclerosis. Our laboratory observed that CB2 deficiency
resulted in increased SMC content within atherosclerotic plaques of Ldlr-/- mice (Netherland et
al. 2010). In agreement with this, activation of CB2 with JWH-133 or HU-308 blunted the
TNFα-induced proliferation and migration of SMCs isolated from human coronary arteries
(HCASMCs) in vitro, by diminishing the activation of the MAPK pathway involved in VSMC
migration and proliferation in humans (Rajesh et al. 2008). This effect was blocked by co-
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administration of CB2 antagonists AM630 and SR144528 but was unchanged by the presence of
a CB1-specific antagonist.
CB2 also modulates protease-mediated vulnerability of atherosclerotic plaques.
Components of the ECM, particularly collagen, play a very important role in maintaining the
structural integrity of vessels and plaques. Degradation of the ECM by MMPs leads to
breakdown of collagen fibers, leaving atherosclerotic plaques weakened and more prone to
rupture (Pasterkamp et al. 2000). The most common MMPs implicated in rupture-prone regions
of atherosclerotic plaques are MMP-1, MMP-3, and MMP-9 (Newby 2005; Dollery and Libby
2006) and an inverse correlation exists between the levels of CB2 and MMP9 content in
atherogenic vessels from humans (Montecucco et al. 2012) and mice (Netherland et al. 2010).
Further, our laboratory found that systemic CB2 deficiency resulted in decreased collagen
content and increased elastin fragmentation in aortic plaques of Ldlr-/- mice after 12 weeks of
HFD, in addition to a 57% increase in MMP9 activity (Netherland et al. 2010). Other studies
have discovered that MMP9 activity in immune cells is suppressed by pharmacological
activation of CB2 and induced by CB2 antagonism (Ghosh et al. 2006; Tauber et al. 2009;
Netherland et al. 2010). In vitro studies have shown that pre-incubation of human primary
neutrophils with JWH-133 results in a reduction in MMP9 release stimulated by TNF-α, which is
blunted with co-administration with AM630 (Montecucco et al. 2012). It is possible that CB2mediated increases in MMP9 are, at least in part, responsible for subsequent increases in
infiltration of immune cells into the plaque area due to the breakdown of structural components
within the luminal endothelium. Interestingly, CB2 deficiency had no effect on collagen content,
elastin fragmentation, or MMP9 activity in plaques of Ldlr-/- mice after 8 weeks of HFD feeding
(Netherland et al. 2010). This suggests that CB2-dependent mechanisms involved in regulation
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of ECM degradation may not come into play in initial stages of plaque development but play a
protective role in more advanced lesions.
Due to their rapid catabolism, the administration of ECs in murine models to evaluate the
effects of chronically elevated EC levels on atherosclerosis is not feasible. To overcome this
limitation, mice lacking either FAAH or MAGL, the enzymes primarily responsible for
catabolism of AEA and 2-AG, respectively, were developed. Mice lacking FAAH cannot
efficiently degrade AEA and therefore accumulate substantially higher AEA levels in brain and
peripheral tissues (Cravatt et al. 2001). FAAH-deficient mice have exaggerated CB1-dependent
behavioral responses to AEA, including hypomotility, analgesia, catalepsy, and hypothermia,
and also display an anti-inflammatory phenotype (Schlosburg et al. 2009; Zimmer 2015). Lenglet
et al. created FAAH-/-ApoE-/- mice to evaluate atherosclerosis in the setting of enhanced AEA
levels due to FAAH deficiency (Lenglet et al. 2013). Compared to ApoE-/- mice, FAAH-/-ApoE-/mice have significantly elevated plasma AEA levels and develop smaller plaques with
characteristics strongly associated with increased vulnerability to rupture, including elevated
neutrophils, increased MMP-9 expression and lower SMC content. Pharmacological inhibition
of FAAH activity in ApoE-/- mice produced very similar results (Hoyer et al. 2014). The role of
cannabinoid receptors in the observed plaque destabilizing effects of FAAH deficiency was not
evaluated in these studies. The fact that AEA is a weak partial CB1 agonist and is nearly
inactive as a CB2 agonist (Sugiura et al. 1995; Gonsiorek et al. 2000; Di Marzo and De
Petrocellis 2012), makes it likely that elevated AEA levels promote formation of less stable
plaque via CB1-mediated mechanisms. Conclusive evidence of the role of CB1/CB2 in
promoting the vulnerable plaque phenotype resulting from impaired FAAH activity will require
additional studies of the effects of either genetic ablation, or pharmacological antagonism, of
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CB1 and CB2 on the plaque phenotype in FAAH-/-ApoE-/- mice and/or ApoE-/- mice treated with
a FAAH inhibitor.
In 2011, Taschler et al. generated MAGL knockout mice to investigate the
pathophysiological consequences of systemic elevation of 2-AG. These mice exhibit
substantially less MAGL activity with concomitant increases in 2-AG levels in all tissues
examined (white adipose, liver and brain) (Taschler et al. 2011). Vujic et. al. determined the
effects of impaired 2-AG metabolism on atherosclerosis by creating MAGL-/-ApoE-/- mice (Vujic
et al. 2016). When fed an atherogenic diet, MAGL-/-ApoE-/- mice develop significantly elevated
2-AG levels in plasma and in aortic tissue compared to ApoE-/- mice. In vitro, macrophages
isolated from MAGL-/-ApoE-/- mice displayed impaired capacity to form foam cells as evidenced
by significantly reduced lipid loading and expression of CD36. Somewhat surprisingly, the
plaques in MAGL-/-ApoE-/- mice were larger than in ApoE-/- mice, even though macrophage and
lipid content were slightly reduced. This apparent discrepancy was explained by the observation
that collagen and SMC content were both substantially increased in MAGL-/-ApoE-/- plaques,
resulting in thicker fibrous caps and a more stable plaque phenotype. Notably, when MAGL-/ApoE-/- mice were given SR144528, plaques increased in size and became less stable resembling
those in ApoE-/- mice, indicating that plaque stabilization in the setting of MAGL deficiency
likely results from 2-AG activation of CB2-dependent mechanisms.
In contrast to the studies performed in the setting of reduced systemic MAGL-mediated
degradation of 2-AG (Hoyer et al. 2014; Vujic et al. 2016), Jehle et. al. employed adoptive
transfer of bone marrow stem cells to evaluated atherosclerosis under conditions of myeloidspecific deficiency in DAG lipase α (DAGLα), a key enzyme in the biosynthesis of 2-AG (Jehle
et al. 2016). Macrophages isolated from ApoE-/- mice reconstituted with bone marrow from
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mice lacking DAGLα had greatly reduced DAGLα activity and 2-AG levels compared to wild
type macrophages; however, plasma levels of 2-AG were notably unchanged and only slightly
reduced in aortic tissue, indicating that macrophage synthesis of 2-AG does not significantly
contribute to circulating 2-AG levels in plasma or in aortic tissue. Consistent with the
correlation established between decreased 2-AG degradation and enhanced plaque size in studies
of MAGL deficiency, myeloid-specific deficiency in 2-AG synthesis correlated with decreased
plaque size. Interestingly, systemic MAGL deficiency and myeloid-specific DAGLα deficiency,
despite having opposite effects on 2-AG levels and plaque size, were both associated with
substantially reduced immune cell infiltration (neutrophil granulocytes and macrophages).
However, only 2-AG elevation resulting from MAGL-deficiency altered the SMC and collagen
content of plaques. Together, these results indicate that macrophage 2-AG exerts a
proinflammatory effect on early lesion formation by accelerating the infiltration of immune cells
into the vessel wall, and suggests that as plaques progress, non-myeloid-derived cells become
active to exert plaque stabilizing mechanisms in response to chronic elevation of 2-AG.
Although FAAH and MAGL have substrates in addition to AEA and 2-AG which may
contribute to the observed effects on atherosclerosis, these studies provide compelling evidence
that alteration of AEA and 2-AG homeostasis affects plaque phenotype. The opposite effects on
plaque stability imparted by systemic MAGL deficiency and systemic FAAH deficiency strongly
suggests that the primary endocannabinoid substrates of these enzymes (2-AG and AEA) are
modulators of plaque phenotype, with AEA activation of CB1-dependent mechanisms
decreasing plaque stability and 2-AG activation of CB2-dependent mechanisms increasing
stability. Further, although there were some contradictory conclusions among the early studies
of the effects of CB2 gene deletion on atherogenesis (Netherland et al. 2010; Delsing et al. 2011;
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Hoyer et al. 2011; Willecke et al. 2011), most likely arising from differences in the genetic
backgrounds of the CB2 knockout mice strains (Cnr2tmZim vs Cnr2tm1Dgen), the atherosclerosisprone murine models (ApoE-/- vs Ldlr-/-), and the methods of analysis used in the studies, the
accumulating evidence from in vivo and in vitro studies has coalesced into a consensus
interpretation that CB2 signaling modulates the formation and progression of atherosclerotic
plaque. Taken together, these results support an anti-atherosclerotic role for CB2 activation, at
least in part, through modulation of inflammatory processes and biochemical signaling pathways
involved in atherosclerotic plaque formation and stability. Further studies could potentially result
in a CB2-selective therapy that aims to reduce inflammation and related plaque vulnerability in
atherosclerosis.
Our laboratory previously found that systemic CB2 gene deletion resulted in changes in
plaque cellularity of Ldlr-null mice fed a HFD for up to 12 weeks, a time frame known to induce
beginning stages of atherosclerotic plaque development. We hypothesized that CB2 modulates
key pathways in later stages of atherogenesis, some of which affect plaque stability and
predisposition to rupture. The clinical relevance of our research lies in the time of analysis, as
most patients do not begin treatment until plaques have already progressed over several decades.
Our lab is also the first, to my knowledge, to assess CB2-dependent effects on plaque
calcification in advanced lesions. Results from this basic research provides a promising strategy
to reduce the burden of atherosclerosis, especially among populations in Western countries
where atherosclerosis and associated complications account for the highest cause of death.
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Specific Aims

Aim 1: Determine the effect of systemic CB2 deletion on plaque cellularity in advanced
atherosclerotic lesions in Ldlr-null mice fed an atherogenic diet.
Aim 2: Determine the effect of systemic CB2 deletion on calcification of advanced plaques in
Ldlr-null mice.
Aim 3: Identify effects of CB2 pharmacological targeting on atherosclerotic and vascular
calcification.
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Abstract

Objective: Cannabinoid receptor 2 (CB2) has been shown to play a role in the early stages of
atherogenesis, however, the involvement of CB2 in advanced atherosclerotic lesion progression
has not yet been examined. To determine if CB2 plays a role in advanced atherosclerotic lesion
composition and progression, we investigated the effects of systemic CB2 gene deletion on
advanced atherogenesis in Ldlr-null mice fed an atherogenic high fat diet (HFD).
Methods and results: Ldlr-/-CB2+/+ (CB2+/+) and Ldlr-/-CB2-/- (CB2-/-) were fed an atherogenic
diet for at least 20 weeks to induce the formation of advanced lesions. Morphometric analysis
revealed no significant difference between the atherosclerotic lesion area in the aortic root of
CB2+/+ and CB2-/- mice after 20 or 24 weeks of HFD, however, there was an increase in
abdominal lesions present in aortas of CB2-/- mice after 20 weeks of atherogenic diet (17.0±1.3
versus 9.0±1.3%, p<0.05). Immunohistochemical staining of the aortic root revealed no
difference in smooth muscle cell (SMC) content between the two genotypes, but a significant
increase in the presence of macrophages in CB2-/- mice compared the CB2+/+ mice (18.8±3.5
versus 8.7±1.7%; p<0.05) after 20 weeks of HFD feeding. The ratio of atherosclerotic lesion
SMCs/macrophages is used as a determinant of lesion stability and was significantly reduced in
CB2-/- mice (0.94±0.09 versus 1.96±0.24; p=0.001). Histological staining revealed no discernible
difference in collagen content in CB2+/+ and CB2-/- mice after 20 weeks. Initial zymography
studies show increased matrix metalloproteinase (MMP)-9 activity in aortic lysates at several
time points in CB2-/- mice compared to CB2+/+ mice, with a 5-fold increase observed after 22
weeks of atherogenic diet.
Conclusions: CB2 receptor deficiency affects late stages of atherogenesis by increasing lesional
macrophage content, decreasing lesion stability through decreasing SMC/macrophage ratio and
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upregulating MMP activity. This data supports a protective role for CB2 in late stages of
atherosclerosis. Information obtained from this study could be used to produce a CB2-specific
therapy aimed at reducing the morbidity and mortality from atherosclerosis by reducing
macrophage accumulation and increasing lesional stability.
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Introduction

Heart disease, specifically coronary heart disease (CHD), is the leading cause of death in
the U.S. (Hansson and Hermansson, 2011; Benjamin et al., 2017). The underlying cause of CHD
is atherosclerosis, a chronic inflammatory disease of the vascular system that is characterized by
the buildup of plaques, composed of lipids and other cellular debris, within arterial walls (Libby,
2012). Atherosclerosis begins when apolipoprotein B (apoB)-containing low-density lipoproteins
(LDL) become sequestered in the intima of arterial walls, rendering them vulnerable to a series
of chemical changes, such as oxidation to form oxLDL. These modifications allow the LDL
particles to mimic molecular patterns associated with pathogens that trigger a pro-inflammatory
immune response. An initial response seen to oxLDL accumulation is the activation of
endothelial cells, characterized by upregulation of integrins that interact with adhesion molecules
that facilitate the entry of immune cells such as monocytes and T lymphocytes (Amberger et al.,
1997). Monocytes are recruited to the subendothelial regions where modified LDL is
accumulated, differentiate into macrophages, and act as phagocytes to engulf the modified LDL.
Expression of scavenger receptors leads to increased influx of LDL particles, leading to the
conversion of macrophages to cholesterol-laden foam cells, a hallmark of atherosclerosis. Foam
cells are retained in plaques and eventually contribute to disease progression by promoting
insufficient lipid metabolism, further compromising fundamental immune functions. Foam cells
that are accumulated in plaques become stationary and frequently die via necrosis or apoptosis,
releasing their internal lipid content and immune components, which contributes to plaque
instability and rupture (Hansson and Hermansson, 2011).
Retention of more lipids and secretion of pro-inflammatory cytokines, such as IFN𝛾, IL1β, and TNFα, by immune cells aids in the multifactorial progression of atherosclerotic plaques.
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Early atherosclerotic lesions are typically found in younger individuals with no clinical
consequences. These lesions are classified as either “fatty streaks” or “intimal thickening”. Fatty
streaks are characterized by foam cell accumulation that lacks a necrotic core, while intimal
thickening is SMC accumulation without the presence of foam cells or lipids (Rosenfeld et al.,
2000). During intermediate stages of lesion development, partial resolution is obtained by the
formation of a fibrous cap from smooth muscle cells (SMCs) and collagen. The fibrous cap acts
to stabilize the contents of the plaque and serves as a barrier to separate platelets from the blood
and clotting factors contained within the lesion (Tabas et al., 2015). Lesions in this stage are
considered to be stable and therefore typically do not result in adverse clinical events (Virmani et
al., 2002). Over time lesions can develop a vulnerable phenotype, rendering them prone to
rupture and initiating acute thrombotic complications. Features of this advanced lesion include
large areas of necrosis, fibrous cap thinning, and increase inflammation. Thinning of the fibrous
cap is caused by increased degradation of collagen and other ECM proteins by proteolytic
enzymes called matrix metalloproteinases (MMPs). Several classes of MMPs exist, and the
gelatinase MMP-9 has gained much interest in the role it plays in atherosclerosis. MMP-9
expression by macrophages within the plaque is positively correlated with oxLDL concentration
(Suzue et al., 2007) and is associated with fibrous cap thinning and plaque rupture (Newby,
2007). Heightened inflammatory responses seen in advanced plaques leads to excess MMP
secretion coupled with diminished capacity of SMCs to synthesize collagen. Weakening of the
fibrous cap can allow fissures to form, exposing macrophage-derived clotting factors to the blood
flowing through the lumen of the artery, leading to detrimental thrombolytic activity that can
result in acute heart attack or stroke.
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The endocannabinoid system consists of endocannabinoid ligands, their catabolic
enzymes, and the receptors at which they function (Smith et al., 2015). Two G-protein coupled
receptors, cannabinoid (CB) type 1 (CB1) and type 2 (CB2), have been characterized (Matsuda
et al., 1990; Munro, 2015). The CB1 receptor is primarily located in the CNS and is responsible
for the psychotropic effects of cannabinoids (Schlicker and Kathmann, 2001). CB2 is primarily
expressed on peripheral immune cells, exerting an immunomodulatory role in response to
cannabinoids (Galiègue et al., 1995; Buckley et al., 2000; Netherland et al., 2010) and further
gaining interest as a drug target for inflammatory diseases (Mach et al., 2008; Pacher and
Ungvari, 2008). Patients with coronary artery disease have elevated levels of circulating
endocannabinoids (Sugamura et al., 2009), and both humans and mice express the CB2 receptor
in atherosclerotic lesions but not in non-diseased vessels (Steffens et al., 2005), suggesting a
functional signaling role for CB2 in atherosclerosis. Further studies have also supported this
finding by showing that cannabinoid therapy reduces atherosclerotic lesion progression, an
incidence that is blunted by co-administration of a CB2-selective antagonist (Steffens et al.,
2005; Zhao et al., 2010b). Several in vitro studies have shown CB2-dependent effects on
monocyte adhesion and infiltration (Rajesh et al., 2007; Zhao et al., 2010a), and our laboratory
was the first to confirm a role for CB2 in early plaque macrophage content by CB2 gene deletion
in a murine model of atherosclerosis (Netherland et al., 2010).
To our knowledge, no other studies have explored the effects of genetic knockdown of
CB2 on advanced atherosclerotic plaque formation in Ldlr-null mice fed an extensive high fat
diet. In this study, we examined the effects of CB2 deletion on the cellularity and stability of
advanced atherosclerotic lesions. Due to the fact that patients typically do not begin intervention
until they are in the advanced stages of atherosclerosis, it is important to uncover treatments that
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can be beneficial in later disease stages. The results from this study may hold important clinical
implications for the development and of CB2-directed drug therapies that could potentially
reduce the burden of unstable atherosclerosis and cardiovascular disease.
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Materials and Methods

Animals and diet-induced atherosclerosis protocol
All mice were housed in a pathogen-free, temperature- and humidity-controlled room in
the Animal Research Facility at East Tennessee State University. Mice were maintained on a
standard chow diet (Ralston Purina, St. Louis, MO) with water provided ad libitum. All animal
procedures were approved by and conducted in accordance with the guidelines administered by
the Institutional Animal Care and Usage Committee of East Tennessee State University and in
conformity with the Public Health Service Policy on Humane Care and Use of Laboratory
Animals published by the National Institutes of Health. CB2 receptor knockout (Buckley et al.,
2000) in the C57BL/J6 background (a generous gift from Dr. Nancy Buckley, California State
Polytechnic University, Panoma, CA) were crossed with Ldlr-null mice backcrossed to the
C57BL/J6 background for ten generations (The Jackson Laboratories, Bar Harbor, ME) to
generate CB2-/-Ldlr-/- (CB2-/-) and CB2+/+Ldlr-/- (CB2+/+) mice as described (Netherland et al.,
2010). Genotyping was performed using PCR analysis of DNA isolated from tail clips using
Ldlr- and CB2-specific primers. Age-matched male and female CB2+/+ and CB2-/- mice were
used for all experiments. At eight weeks of age, groups of male and female CB2+/+ and CB2-/mice were placed on an atherogenic, high-fat diet (HFD) consisting of 21% fat and 0.15%
cholesterol (Harlan Teklad, Madison, WI) for at least 20 weeks.

Analysis of atherosclerosis
Animals were euthanized as previously described (Netherland et al., 2010). Briefly, mice
were anesthetized and perfused via left ventricle with phosphate-buffered saline (PBS). The heart
and aorta were dissected and the aortas were placed in 10% formalin at 4ºC and the heart tissue
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was embedded in OCT medium and snap frozen. OCT-embedded hearts were mounted in a
Leica CM1850 cryostat and 8µm sections of the aortic root were collected. Tissue cryosections
were stained for neutral lipids using oil-red O and counterstained with hematoxylin as described
(Netherland et al., 2010; Netherland-Van Dyke et al., 2015). Digital images were captured using
an EVOS FL digital imaging system (Electron Microscopy Sciences, Hartfield, PA). Fixed aortas
were prepared using en face method and lipids were stained using Sudan IV reagent.
Atherosclerotic lesions present in the aortic root and throughout the aorta were measured
morphometrically using the ImageJ software (NIH, Bethesda, MD). Measurements were
independently performed by two observers in a blind fashion.

Physiological parameters
Blood samples were collected and analyzed as previously described (Netherland et al.,
2010). Briefly, overnight-fasted blood was collected from anesthetized mice via cardiac
puncture. Plasma was separated by centrifugation and analyzed for total plasma cholesterol and
triglycerides levels using commercially available kits (Pointe Scientific, Inc., Canton, MI)
according to the manufacturer’s protocol.

Histological and immunohistochemical staining
Prior to histological staining, fresh frozen aortic root sections were thawed and air dried
for 1 h and rehydrated. The presence of collagen was determined using Mason’s Trichrome
staining. For immunohistochemical staining, cryosections were thawed and air dried at room
temperature for 1h and fixed in ice-cold acetone for 10min. Sections were dried and pretreated
with 1% H2O2 in PBS for 0.5h before being rinsed and blocked in normal serum for 0.5h at room
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temperature. Detection of VSMCs and macrophages were accomplished by using anti-smooth
muscle α-actin (ThermoFisher, Waltham, MA; RB-9010PO) (diluted 1:200) and MOMA2
(Chemicon International, Temecula, CA; MAB1852) (diluted 1:1000), respectively. Sections
were developed using a Vector Labs Elite ABC kit (Burlingame, CA) and counterstained with
methyl green at 55ºC for 5 min. Quantification of staining was performed by use of computerassisted image analysis using ImageJ, and a standard threshold for staining that discriminated
between positive and negative lesion areas was applied to all specimens analyzed. All
evaluations were performed by a trained observer unaware of genotype or sample type.
Zymography
Aortic lysates were resolved on 10% SDS-PAGE gels containing gelatin (1mg/ml) and
electrophoresed under nonreducing conditions. Gel proteins were renatured, washed, and
activated as previously described (Netherland et al., 2010). Proteolytic activity was represented
as zones of lysis that could be visualized in the background of Coomassie blue staining.
Quantification was performed using ImageJ software.
LC-MS/MS measurement of aortic endocannabinoid levels
Quantification of aortic 2-arachydonoyl glycerol (2-AG) and anandamide (AEA) levels
was performed using a Shimadzu liquid chromatography system coupled to a Shimadzu IT-TOF
mass spectrometer with an electrospray (Columbia, MD) as previously described (Garst et al.,
2016). Briefly, analytes were extracted using a liquid-liquid extraction method using toluene,
evaporated to dryness under nitrogen and reconstituted in acetonitrile. Spiked standards were
prepared using octadeuterated internal standards. Injections were performed with 10µL of
reconstituted sample at a flow rate of 0.200mL/min and detection was achieved utilizing a direct
MS/MS method in positive electrospray. Amount of 2-AG and AEA was normalized to the
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weight of the tissue sample.
Statistical Analysis
Data is presented as mean SEM. Data were analyzed by Student’s t-test or one-way ANOVA
using SigmaPlot Software. p<0.05 was considered to be statistically significant.
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Results

CB2 deficiency affects the extent of lesion formation in the distal aorta

Throughout the study, no significant effect on plasma lipid levels was observed between
the two genotypes (Figure 2.1c-d). Increases in mean body mass were observed in CB2-/- mice
compared to CB2+/+ mice after HFD feeding for 20 weeks (males: 42.1±1.9 versus 34.1±2.2
grams, respectively; p=0.01, females: 27.4±1.7 versus 22.8±0.6 grams, respectively; p=0.003)
and 24 weeks (males: 42.1±2.1 versus 33.2±2.1 grams, respectively; p=0.01, females: 32.6±1.7
versus 22.3±1.0 grams, respectively; p=0.0001) (Figure 2.1a-b). Atherosclerotic lesion
development was quantified in the aortic root and throughout the thoracic and abdominal aorta
(Figure 2.2). No difference in mean percent of aortic root occupied by lesion was observed
between CB2+/+ or CB2-/- mice after 20 weeks (55.7±3.8 versus 52.2±3.7%, respectively;
p=0.527) or 24 weeks (53.2±1.3 versus 52.3±2.6%, respectively; p=0.734) of HFD feeding.
Examination of the extent of atherosclerosis in en face prepared aortas was performed in
designated aortic segments: aortic arch, thoracic aorta, abdominal aorta. Quantification revealed
a significant increase (~1.9 fold) in the percentage of abdominal aorta surface occupied by
lesions in CB2-/- mice compared to CB2+/+ mice after 24 weeks of HFD (17.0±1.3 versus
9.0±1.3%, respectively; p=0.002). However, no difference in percentage of area occupied by
lesion was observed between CB2+/+ and CB2-/- mice in the aortic arch (57.1±1.8 versus
54.9±2.0%, respectively; p=0.4) or thoracic aorta (17.4±2.6 versus 12.9±2.1%, respectively;
p=0.2).
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Figure 2.1 CB2 deficiency increases weight in Ldlr-null mice after 20 weeks of atherogenic diet.
Weights of female (A) and male (B) CB2+/+ and CB2-/- mice after 20 and 24 weeks of
atherogenic diet. Serum levels of cholesterol (C) and triglycerides (D) from CB2+/+ and CB2-/mice after 20 and 24 weeks of atherogenic diet. Data represents means (n≥8)±SEM. *p<0.05;
**p<0.001.
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Figure 2.2 CB2 deficiency does not affect extent of atherosclerosis development in the aortic
root but does affect plaque development in the abdominal aorta of Ldlr-null mice after 20 weeks
of HFD. (A) Representative photomicrographs of oil red O-stained aortic root cross sections
from CB2+/+ and CB2-/- mice after 20 weeks of HFD. B) Representative photographs of en faced
aortas from CB2+/+ and CB2-/- mice stained with Sudan IV after 24 weeks of HFD.
Quantification of the percent lesion area in the aortic root (C) and aortic lumen (D) of CB2+/+ and
CB2-/- mice. Data represents means (n=6-8)±SEM. *p<0.05 compared to CB2+/+

CB2 deficiency slightly elevates aortic 2-AG levels with no effect on AEA
Aortas were analyzed to determine levels of two endocannabinoids, 2-arachydonoyl
glycerol (2-AG) and anandamide (AEA) (Figure 2.3). LC-MS/MS analysis of aortic tissue
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revealed no difference in either 2-AG or AEA between either genotype or chow-fed controls
after 8 weeks of HFD. After 12 weeks of HFD, aortic levels of 2-AG and AEA were increased
significantly in both CB2+/+ and CB2-/- mice compared to chow-fed controls (CB2+/+ versus chow
2-AG, p=0.004; CB2+/+ versus chow AEA, p=0.003; CB2-/- versus chow 2-AG, p=0.0001; CB2-/versus chow AEA, p=0.0006). 2-AG levels were significantly higher in CB2-/- mice compared to
CB2+/+ mice (0.6±0.05 versus 0.4±0.04 nM/mg, respectively; p=0.03). Although aortas from
CB2-/- mice had slightly more AEA than CB2+/+ mice, the levels were not statistically significant
between genotypes (155.2±11.3 versus 146.3±11.8 nM/mg, respectively; p=0.6).
After 24 weeks of HFD, the aortic levels of 2-AG were further increased significantly compared
to the levels after 12 weeks of HFD for both genotypes, with aortas of CB2-/- mice having
significantly more 2-AG than CB2+/+ mice (1.7±0.30 versus 0.7±0.05 nM/mg, respectively;
p=0.0004). Interestingly, after 24 weeks the aortic levels of AEA decreased dramatically to
levels below that of chow controls for both CB2-/- mice (0.6±0.06 versus 80.4±13.6 nM/mg;
p<0.001) and CB2+/+ mice (0.7±0.1 versus 80.4±13.6 nM/mg; p<0.001). The AEA levels
between both genotypes at this time point were comparable (p=0.2). Elevations of
endocannabinoids in relation to obesity have been accompanied with subsequent decreases in
fatty acid amide hydrolase (FAAH) in humans (Engeli et al., 2005). To parallel the increased
body mass and 2-AG levels we observed in CB2-/- mice, we also observed a reduction in protein
expression of FAAH in CB2-deficient aortas; however, these levels never reached significance
(Supplemental Figure 2.6).
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Figure 2.3 CB2 deficiency increases aortic 2-AG levels in Ldlr-null mice. Concentrations of 2AG (panel A) and AEA (panel B) in aortas from CB2+/+ and CB2-/- mice after HFD feeding for 0,
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CB2 deficiency increases macrophage accumulation in atherosclerotic lesions

Macrophage accumulation in the intima of atherosclerotic lesions was readily detected
after 20 weeks of atherogenic diet in both CB2+/+ and CB2-/- mice as determined by
immunostaining with a MOMA2 antibody (Figure 2.4b). Quantification of the areas staining
positive for MOMA2 revealed a significant (~2.2 fold) increase in the macrophage content of
aortic root lesions in CB2-/- mice compared to CB2+/+ mice (18.8±3.5 versus 8.7±1.7%,
respectively; p=0.03). Immunostaining with a smooth muscle α-actin antibody revealed
migration of SMC from the intima towards the lumen in lesions of wildtype and CB2-deficient
mice (Figure 2.4a). Quantification showed equivalent SMC immunoreactivity in both CB2+/+ and
CB2-/- lesions (14.0±1.1 versus 15.2±0.6%, respectively; p=0.4). Unstable atherosclerotic lesions
contain a reduced ratio of lesional VSMCs relative to macrophages (Tabas et al., 2015). We
observed a significant decrease in the ratio of VSMCs relative to macrophages in lesions of CB2/-

mice compared to CB2+/+ mice (0.94±0.09 versus 1.96±0.24, respectively; p=0.001) (Figure

2.4e). Fibrous caps were also significantly thinner in CB2-/- mice compared to CB2+/+ mice
(52.8±3.8 versus 75.7±5.9 µm, respectively; p=0.002) (Figure 2.4f). These results indicate that
although CB2+/+ mice exhibit equally large lesions, their cellular composition is characterized by
a more stable phenotype.
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Figure 2.4 Cellular composition of atherosclerotic lesions in CB2+/+ and CB2-/- mice fed an
atherogenic diet for 20 weeks. Representative photomicrographs of aortic root cross sections
from CB2+/+ and CB2-/- mice fed an atherogenic diet for 20 weeks and immunohistochemically
stained for SMCs (A) and macrophages (B) using SM α-actin and MOMA2 antibodies,
respectively. Quantification of SMC (C) and macrophage (D) content of aortic root lesions from
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CB2+/+ and CB2-/- mice. Positive immunostaining was quantified and represented as the
percentage of the total lesional area. E) Ratio of VSMCs relative to macrophages within
atherosclerotic lesions in CB2+/+ and CB2-/- mice. Ratios were calculated from percentage of
positive SM α-actin signal relative to positive MOMA2 signal for all samples. F) Quantification
of fibrous cap thickness. Each data point represents an average of 8-10 measurements from each
mouse. Data represents means (n=6-8)±SEM.*p<0.05, **p<0.001

CB2 deficiency alters the ECM of atherosclerotic lesions
Collagen content of aortic root lesions was assessed by use of Mason’s trichrome staining
(Figure 2.5a), which revealed no statistical difference between CB2+/+ and CB2-/- mice after 22
weeks of atherogenic diet (45.2±3.7 versus 50.8±4.6%, respectively; p=0.4). Our laboratory
previously detected increased MMP9 activity in atherosclerotic lesions in the aortic root, as well
as isolated peritoneal macrophages, of CB2-/- mice in early lesions (Netherland et al., 2010). We
analyzed lysates prepared from the aortic arches of CB2+/+ and CB2-/- mice to determine MMP9
activity, as this portion of the aorta displays extensive atherosclerosis. Zymography of aortic arch
lysates from CB2+/+ and CB2-/- mice showed a band of gelatinase activity at 92kDa,
corresponding with the approximate weight of MMP9 (Figure 2.5b). Quantification of the
zymograms confirmed larger zones of lysis corresponding to MMP9 activity in lysates from
CB2-/- mice compared to those from CB2+/+ after 22 weeks of atherogenic diet (4728.9±1306.1
versus 900.6±276.4, respectively; p=0.04).
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Figure 2.5 Collagen content and MMP9 activity in advanced atherosclerotic lesions in CB2+/+
and CB2-/- mice. A) Representative photomicrographs of atherosclerotic lesions in aortic root
cross sections stained for collagen after 22 weeks of atherogenic diet (pink). B) Zymogram of
MMP9 activity from aortas of CB2+/+ and CB2-/- mice after 22 weeks of atherogenic diet. C)
Quantification of the collagen content of aortic root lesions from CB2+/+ and CB2-/- mice (n=6).
The amount of collagen is represented as a percentage of total lesional area. D) Digital
quantification of the MMP9 zones of lysis in the zymogram (n=3). Graphical representation is
shown as the band density for 15 µm of protein. Data represented as mean±SEM. *p<0.05.
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Discussion
Several in vivo and in vitro studies suggest a role for CB2 in atherosclerosis (Steffens et
al., 2005; Mach et al., 2008; Rajesh et al., 2008; Netherland et al., 2010; Zhao et al., 2010c;
Netherland-Van Dyke et al., 2015), however, these studies have not been carried out to mimic
advanced lesion progression. In the current study, we directly examined the role of CB2 in more
advanced atherosclerosis by investigating the effects of systemic CB2 gene deletion on
atherosclerosis in Ldlr-null mice fed an atherogenic diet for an extended period of up to 24
weeks. Our study showed that deletion of CB2 did not affect the lesion area in the aortic root of
Ldlr-null mice despite the fact that CB2 activation has been shown to decrease lesion size
previously. Pharmacological studies have shown that administration of exogenous CB ligands
reduced aortic root atherosclerotic lesion size in ApoE-null mice in a CB2-dependent manner
(Steffens et al., 2005; Zhao et al., 2010c). Alternatively, our laboratory failed to detect a
difference in aortic root lesion size after administration of WIN55,212-2, a CB1/CB2 mixed
agonist, in Ldlr-null mice (Netherland-Van Dyke et al., 2015). Contradiction in these results
could be attributed to differences between the two murine models of atherosclerosis, as it is well
documented that Ldlr-/- and ApoE-/- mice show variation in lipoprotein profiles and onset of
atherogenesis (Daugherty and Rateri). Our study did, however, show an increase in the amount
of lesion that occupied the abdominal aorta in CB2-deficient mice. No study until now has
shown how CB2 deletion in Ldlr-null mice differentially affects lesion development in specific
regions of the aorta.
Our laboratory and others have previously shown a CB2-dependent role in macrophage
accumulation in early aortic root lesions (Steffens et al., 2005; Netherland et al., 2010; Zhao et
al., 2010c). The current study confirms that CB2 deficiency also increases macrophage
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accumulation in more advanced atherosclerotic lesions, suggesting that CB2 signaling plays a
role in monocyte/macrophage accumulation with effects lasting into later stages of atherogenesis.
The result is consistent with studies showing that blocking CB2 signaling results in increased
transendothelial migration of monocytes into the vessel wall due to upregulation of adhesion
molecules (VCAM-1, ICAM-1, p-selectin) on the surface of endothelial cells (Rajesh et al.,
2007; Zhao et al., 2010b). However, our study did not measure expression of endothelial cell
adhesion molecules, and to our knowledge, tissue macrophage proliferation has never been
assessed in a CB2-dependent way. Therefore, it is possible that in advanced lesions the increased
macrophage content of CB2-/- lesions is due to increased proliferation of lesional macrophages
and not to increased transendothelial migration of blood monocytes. We plan to address this
issue in future studies.
Proliferation and migration of VSMCs is an important mechanism for stabilizing
atherogenic plaques. Our laboratory previously showed that CB2 deficiency increases SMC
migration to the fibrous cap regions in early lesions (Netherland et al., 2010) and in vitro studies
have shown attenuation of TNFα-induced SMC proliferation and migration in a CB2-dependent
manner (Rajesh et al., 2008). However, our current study failed to show CB2-dependent loss of
SMC staining in late atherosclerotic lesions. There are a few possible explanations for these
somewhat contradictory results. First, there are many biochemical cell signaling pathways that
can affect SMC migration and proliferation, and it is possible that CB2 modulation of these
processes is overshadowed by compensatory pathways that become more involved as the disease
progresses. Secondly, recent studies involving lineage tracing of cells in atherosclerotic plaques
has provided evidence of phenotype-switching of certain cell types throughout atherogenesis
(Lineage tracing of cells involved in atherosclerosis., 2016). Notably, this study found that
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almost 20% of CD68-positive macrophage-like cells did not originate from the myeloid lineage,
but instead, were derived from mature SM cells. It is possible that CB2 signaling affects SMC
phenotype switching. CB2 activation results in an anti-inflammatory response, and its plausible
that CB2 deletion increases the transition of SMCs to a macrophage-like phenotype, resulting in
increased expression of inflammatory genes. Experiments utilizing a combination of genetic fate
mapping and single cell expression analysis in the setting of CB2 gene deletion would have to be
employed in a murine model of atherosclerosis to provide insight into the role of CB2, if any, in
this process.
Although we previously showed that CB2 deletion resulted in decreased collagen content
in early atherosclerotic lesions, the current study did not find an appreciable difference in
collagen content between the two genotypes in late lesions. As our results were calculated as a
percentage of total lesion area, an increase in acellular regions of lesions from CB2-/- mice
affecting the total lesion area could be responsible for this result. Another explanation for this
could be the fact that SMC content was similar between both groups, and SMCs are the primary
producer of collagen. Our data suggests that CB2 modulation of SMC proliferation is only
observed early in disease development, and becomes less prevalent in advanced stages.
Expression of MMP9 by immune cells is suppressed in the presence of cannabinoid
agonists (Ghosh et al., 2006; Tauber et al., 2009), while a dose-dependent increase in MMP9
expression has been observed in macrophages exposed to a CB2-specific antagonist (Netherland
et al., 2010). Consistent with this, we found an increase in MMP9 activity in aortic arch lysates
of CB2-deficient mice. Increased serum MMP9 levels have been associated with increased risk
of acute coronary events in patients with atherosclerosis (Kai et al., 1998; Inokubo et al., 2001)
and increased MMP9 expression in atherosclerotic plaques is associated with disease progression
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(Wågsäter et al., 2011). Another factor contributing to plaque instability beyond ECM
degradation is a reduced ratio of VSMCs to macrophages within the lesion (Tabas et al., 2015),
and our data showed a significant reduction in this ratio associated with CB2 gene deletion.
However, as mentioned before, lineage tracing has provided evidence for switching of VSMCs
to a macrophage-like phenotype, which potentially could affect this result if the phenotype
switching is affected by CB2 signaling. Due to the lack of a definitive lineage tracing study in
the setting of CB2 gene deletion, a considerable ambiguity exists regarding which cells are in
fact derived from SMC mesenchymal lineage versus macrophage myeloid lineage.

The role of the ECS and CB1 specifically in the control of food intake, energy balance
and body mass has been well-documented (Kirkham et al., 2002; Cota et al., 2003; Matias et al.,
2006; Dodd et al., 2009). CB1 activation results in increased adipocyte differentiation and
lipogenesis (Cota et al., 2003; Gasperi et al., 2007), and, accordingly, CB1 inhibition has been
shown to protect against HFD-induced weight gain and also reduces body weight in obese
animals and humans (Després et al., 2005; Pi-Sunyer et al., 2006; Scheen and Van Gaal, 2007;
Dol-Gleizes et al., 2009; Engeli, 2012). The observed increases in body weight and aortic 2-AG
levels in CB2-deficient mice are likely associated with each other, and could be explained by
increased CB1 expression/signaling, as it is possible that CB1 is upregulated as a compensatory
mechanism due to the absence of CB2. It has also been observed that CB1 expression in adipose
tissue is increased in the presence of HFD-induced obesity in mice (Osei-Hyiaman et al., 2005),
and 2-AG levels are increased in epididymal fat pads of obese animals in comparison to lean
mice (Matias et al., 2006). Further, 2-AG administration in the limbic forebrain of animals
increases food intake in a CB1-mediated, dose-dependent manner (Kirkham et al., 2002). It
appears that CB1 and 2-AG both exhibit a “cause-and-effect” phenomenon, where both are
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upregulated as a result of obesity, but also promote obesity through their biological functions. It
is also likely that upregulation of CB1 affects 2-AG production, as biosynthesis of 2-AG in
pathological conditions appears to occur selectively, requiring retrograde regulation mediated by
CB1 (Di Marzo and De Petrocellis, 2012).

Alterations in the concentrations of 2-AG and AEA occur in many pathological
conditions, and it is not uncommon to see opposite regulation of the two (Ligresti et al., 2009).
The observed decrease in aortic AEA levels in both genotypes after 24 weeks of HFD is likely
due to increased leptin production occurring in response to enhanced fat storage. Leptin is a
hormone secreted by adipocytes that modulates food intake and energy balance by upregulating
anorexigenic factors (Di Marzo et al., 2001; Brennan and Mantzoros, 2006). Several studies have
shown an inverse correlation between AEA and leptin levels, and leptin inhibits endogenous
AEA levels in the brain and uterus of rodents as well as in human blood (Maccarrone et al.,
2003; Di Marzo et al., 2004; Maccarrone et al., 2005).

Collectively, these results provide additional evidence that supports a protective role of
CB2 signaling in the progression of atherosclerosis. Previous studies reported an anti-atherogenic
role for CB2 in early atherosclerotic lesion formation and progression, and our present study
provides the first direct evidence of CB2 gene expression playing a role in modulating the
cellular composition and stability of advanced lesions. These results support a potential use for
pharmacological compounds with selective activity at CB2 in the treatment of atherosclerotic
lesions which have progressed to an advanced stage. Uncovering a treatment regimen which
could provide beneficial modifications of lesion compositions in later stages of disease
development. This would be extremely clinically relevant, as most affected patients do not begin
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receiving pharmacological intervention until after suffering from an initial acute episode
resulting from rupture of an advanced lesion.
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Supplemental Figure 2.6 Effects of CB2 gene deletion of aortic FAAH levels in Ldlr-null mice.
A) Immunoblot showing levels of FAAH in aortic arch lysates from CB2+/+ and CB2-/- mice after
14 and 24 weeks of HFD. B) Quantification of FAAH levels relative to the housekeeping
protein, HSC70. Data are means±S.D. (n=2) for each genotype.
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Abstract
Objective: Calcification of atherosclerotic lesions is a risk factor for future adverse
cardiovascular events. Cannabinoid receptor type 2 (CB2) signaling modulates bone remodeling
processes and affects development of atherosclerotic lesions. To determine if CB2 signaling
impacts lesion calcification, we investigated the effects of systemic CB2 gene deletion on the
development of calcified lesions in Ldlr-null mice fed an atherogenic diet.
Methods and results: At 8 weeks of age, Ldlr-/-CB2+/+ (CB2+/+) and Ldlr-/-CB2-/- (CB2-/-) mice
were placed on an atherogenic diet for 20-24 weeks. Morphometric analysis of von Kossastained aortic root cross sections revealed a significant increase in calcium deposition in CB2-/mice compared to CB2+/+ mice (13.0±1.1 versus 5.6±1.2%; p<0.05) after 20 weeks of
atherogenic diet. Biochemical analysis of the activity of the osteoclast marker enzyme, tartrateresistant acid phosphatase (TRAP), revealed significantly less osteoclast activity in aortic root
lesions of CB2-/- mice compared to CB2+/+ mice (9.7±0.05 versus 4.9±0.16%; p<0.05).
Immunofluorescent staining of aortic root cross sections with an antibody against soluble
receptor activator of nuclear factor kappa-B ligand (RANKL) similarly showed reduced RANKL
expression in lesions from CB2-/- mice compared to CB2+/+ mice (0.2±0.0004 versus
0.04±0.0040; p<0.001). Immunoblotting detected significantly decreased expression of
osteogenic regulatory proteins runt-related transcription factor 2 (Runx2) (p<0.05) and
osteopontin (OPN) (p<0.05). Semiquantitative RT-PCR analysis of RNA extracted from aortic
arch tissue revealed elevated mRNA levels of osteogenic genes, alkaline phosphatase (ALP),
type I collagen (ColI), and osteoprotegerin (OPG) in CB2-/- mice (P<0.05 for all genes).
Conclusions: CB2 receptor deficiency increases calcification of atherosclerotic lesions in Ldlrnull mice, at least in part, by enhancing osteoblast activity and decreasing osteoclast activity
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within lesions. Our data indicates a novel therapeutic potential for CB2 agonists to reduce lesion
calcification, and therefore the risk for myocardial infarction and stroke.
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Introduction

Cardiovascular disease (CVD) claims more lives every single year than all forms of
cancer combined. The most prevalent form of CVD is coronary artery disease (CAD), a disease
that is responsible for over 360,000 deaths every year in the U.S. (Benjamin et al., 2017).
Atherosclerosis is the underlying cause of CAD and other CVDs, resulting in myocardial
infarction, stroke, and peripheral vascular disease. Atherosclerosis is a chronic inflammatory
disorder that progresses over the course of decades and is characterized by the buildup of
atherosclerotic lesions (or plaque) containing lipids and immune cells within the walls of arteries.
The disease is multifaceted, initially elicited by the subendothelial retention of lipoproteins and
gradually evolving with the infiltration of inflammatory cells, the proliferation and migration of
smooth muscle cells (SMCs), cellular apoptosis and necrosis, arterial remodeling and
calcification, all of which may lead to plaque rupture and thrombosis (Bui et al., 2009; Bentzon
et al., 2014). The majority of plaques are subclinical; however, a percentage of individuals
develop unstable lesions which puts them at risk for adverse clinical outcomes.
Several factors are attributed to the formation of unstable plaques, such as increased
proteolytic activity of extracellular matrix (ECM) components, necrotic core formation, and
calcification. In particular, calcification of atherosclerotic plaques has gained increasing
recognition over the past 15 years due to consistent findings of a correlation with increased risk
of cardiovascular mortality (Sage et al., 2010). Vascular SMCs (VSMC) are key contributors to
plaque calcification as a result of their phenotypic plasticity (Byon et al., 2008). VSMCs
typically exhibit a contractile phenotype and are present in the medial layer of arteries to
function in maintaining vascular tone. In response to injury or disease, VSMCs can be induced to
switch to a synthetic phenotype in order to proliferate and migrate to sites in need of repair
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(Shanahan et al., 1993; Shanahan and Weissberg, 1998). This is seen in the context of
atherosclerosis, when VSMCs migrate into the intima and create a protective fibrous cap at site
of injury. In normal instances, VSMCs are highly regulated and return to their contractile, nonproliferating phenotype. However, regulatory signals become compromised in the setting of
atherogenesis, causing dysregulation in VSMC differentiation (Iyemere et al., 2006). Under these
conditions, VSMCs transdifferentiate to a synthetic phenotype characterized by features of other
mesenchymal lineages, such as osteoblasts (Tintut et al., 2003).
Osteoblasts are cells that synthesize a matrix that then becomes mineralized, and are
important in the formation and remodeling of bones. Runt-related transcription factor 2 (Runx2)
is a complex transcription factor necessary for the differentiation of osteoblasts (Ducy and
Karsenty, 1995; Komori et al., 1997; Otto et al., 1997), and is considered to be the master
regulator of osteoblastogenesis. Regulation of osteoblast differentiation by Runx2 is dynamic,
and a shift from positive to negative regulation is seen from initial stages to final stages of
osteoblast maturation. Runx2 also regulates the expression of several osteoblast marker genes,
such as osteocalcin (Ducy and Karsenty, 1995), collagen I (ColI), osteopontin (OPN) (Ducy et
al., 1997; Sato et al., 1998), osteoprotegerin (OPG) (Thirunavukkarasu et al., 2000), and alkaline
phosphatase (ALP) (Bruderer et al., 2014). These proteins provide a variety of functions in the
regulation of calcification, both negative and positive. For example, increased ALP is needed for
progression of osteoblast maturation (Takeuchi et al., 1996) while OPN is a potent negative
regulator of calcification and binds to apatite crystals to inhibit their growth (Wada et al., 1999).
The endocannabinoid system consists of two known G-protein coupled receptors, termed
cannabinoid receptor 1 (CB1) and 2 (CB2), endogenous ligands (called endocannabinoids) for
these receptors, and their metabolic enzymes. CB1 is largely expressed in the central nervous

88

system where it mediates the psychotropic effects associated with cannabinoids. CB2 is
primarily expressed in peripheral immune cells, such as macrophages and T cells (Munro et al.,
1993; Galiègue et al., 1995; Buckley et al., 2000), subsequently producing immunosuppressive
effects. Emerging evidence indicates a role for the endocannabinoid system and CB2 specifically
in atherosclerosis. Circulating endocannabinoid levels are increased in patients with coronary
artery disease (Sugamura et al., 2009) and CB2 expression is present in atherosclerotic plaques
but not in healthy vessels (Steffens et al., 2005a). Specifically, CB2 expression is upregulated in
plaque macrophages (Carlisle et al., 2002) and has been implicated in pathways involved with
ongoing atherogenesis (Steffens et al., 2005a; Montecucco et al., 2008; Netherland et al., 2010).
Interestingly, CB2 deficient mice display an age-related decrease in bone mass
resembling osteoporosis, and polymorphisms in CNR2, the gene encoding CB2, are strongly
associated with osteoporosis in postmenopausal women (Bab et al., 2009). Further, a negative
correlation exists between osteoporosis and atherosclerotic calcification in humans (Hamerman,
2005; Farhat and Cauley, 2008; Stojanovic et al., 2011). Therefore, we hypothesized that CB2
plays a protective role in calcification of atherosclerotic plaques. In this study, we have provided
the first evidence to our knowledge that CB2 inhibits lesional osteogenic processes and
calcification in a mouse model of atherosclerosis. Furthermore, we identify key osteogenic
regulatory mechanisms altered by CB2 deficiency within lesions and aorta. These finding
provide molecular insights into the regulation of atherosclerotic calcification by CB2, and
uncover potentially novel therapeutic uses for CB2 agonists to reduce adverse complications of
atherosclerotic calcification.
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Materials and Methods

Animals and diet-induced atherosclerosis protocol
All mice were housed in a pathogen-free, temperature- and humidity-controlled room in
the Animal Research Facility at East Tennessee State University. Mice were maintained on a
standard chow diet (Ralston Purina, St. Louis, MO) with water provided ad libitum. All animal
procedures were approved by and conducted in accordance with the guidelines administered by
the Institutional Animal Care and Usage Committee of East Tennessee State University and in
conformity with the Public Health Service Policy on Humane Care and Use of Laboratory
Animals published by the National Institutes of Health. CB2 receptor knockout mice in the
C57BL/J6 background (a generous gift from Dr. Nancy Buckley, California State Polytechnic
University, Panoma, CA) were crossed with Ldlr-null mice as previously described (Netherland
et al., 2010). Age-matched CB2+/+ and CB2-/- mice were used for all experiments. At eight weeks
of age, groups of CB2+/+ and CB2-/- mice were placed on an atherogenic, high-fat diet (HFD)
consisting of 21% fat and 0.15% cholesterol (Harlan Teklad, Madison, WI) for 20-24 weeks to
induce the formation of advanced atherosclerotic lesions.

Histological and immunofluorescent staining
Animals were euthanized as previously described (Netherland et al., 2010). Briefly, mice
were anesthetized and euthanized by cardiac perfusion with 10 ml ice-cold phosphate buffered
saline. The heart and aorta were dissected and snap frozen at -80°C, with heart tissue embedded
in OCT medium. OCT-embedded hearts were mounted in a Leica CM1850 cryostat and 8µm
sections of the aortic root were collected. Tissue cryosections were stained for calcium
deposition using von Kossa method. In situ osteoclast activity was measured biochemically using
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a tartrate-resistant acid phosphatase (TRAP) leukocyte kit (Sigma, St. Louis, MO) according to
the manufacturer’s protocol. For immunofluorescent staining, tissue cryosections were
thoroughly rinsed with tris-buffered saline containing 0.1% tween 20 (TBS-T) and blocked in
5% serum in PBS-T for 1h at RT. Sections were then probed with an antibody against sRANKL
(ProSci Inc, Poway, CA; #3963) (1:200 in blocking buffer) overnight at 4°C, rinsed with PBS-T,
and incubated with a FITC-conjugated secondary antibody (Santa Cruz Biotechnologies, Dallas,
TX) (1:1000 in blocking buffer) for 1h at RT in the dark. Sections were rinsed three times with
PBS-T, once with PBS, and mounted with Pro-Long mounting medium with DAPI
(ThermoFisher, Waltham, MA). Digital images were captured using an EVOS FL digital
imaging system (Electron Microscopy Sciences, Hartfield, PA). Computer-assisted
morphometric analysis was performed using ImageJ software (NIH, Bethesda, MD). A threshold
for positive staining was measured and applied uniformly to all images. For each sample, a
minimum of four slides containing four cross sections were evaluated and averaged. All
measurements were performed by a trained observer in blinded fashion.

Immunoblotting
Aortic arch tissue was lysed in buffer containing 20 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 1% Triton-X100, 1% DOC, 1 mM EDTA, 0.05% SDS and freshly supplemented with
protease inhibitor cocktail (Sigma, St. Louis, MO) by use of a handheld homogenizer. Lysates
were centrifuged at 12,000 x g for 15 min at 4°C and the supernatant was collected and the
protein content determined using a microBCA kit (ThermoFisher, Waltham, MA). Samples
containing 20µg of protein were denatured at 95°C in the presence of DTT for 5 min and
subjected to electrophoresis using 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA). Proteins were
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transferred to a polyvinylidene fluoride membrane, blocked in TBS-T containing 5% non-fat
milk and probed with specific antibodies to Runx2 (Santa Cruz, Dallas, TX; sc-10758) (1:2000),
OCN (MyBioSource, San Diego, CA; MBS2003553) (1:1000), and OPN (R&D Systems,
Minneapolis, MN; AF808) (1:3000) overnight at 4 ̊C. After incubation with proper horse radish
peroxidase (HRP) conjugated secondary antibody (Santa Cruz, Dallas, TX) (1:2000), membranes
were developed using Amersham ECL Prime Western Blotting Detection Reagent (GE
Healthcare Bio-Sciences, Pittsburgh, PA) and a Fujifilm Fla-4000 imager. Membranes were
stripped and probed with an HSC70 antibody (Abcam, Cambridge, United Kingdom; ab19136)
(1:10,000) to serve as a loading control. Quantitation of band densities was performed using
ImageJ software (NIH, Bethesda, MD).

Semiquantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from aortas using Direct-zol RNA MiniPrep (Zymo Research,
Irvine, CA). The concentration and purity (A260/280) of RNA samples was determined using a
Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE). RT-PCR
was carried out using a Verso HotStart 1-Step kit (Life Technologies, Carlsbad, CA) according
the manufacturer’s instructions in an Eppendorf Mastercycler (Hamburg, Germany). Typical
cycling reactions were a first cycle of 15 minutes at 50°C, 2 minutes at 95°C followed by 30-35
cycles of 95°C for 20 seconds, 50-60°C for 30 seconds and 1 minute at 72°C. Conditions were
optimized so that none of the PCR products analyzed reached a plateau by the end of the
amplification protocol, i.e. they were in the exponential phase of amplification. The reactions
were run along with a no-RNA sample negative control and the absence of genomic DNA
contamination was verified by performing control reactions in which the reverse transcriptase
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was inactivated by heating at 95°C for 5 minutes prior to performing the standard RT-PCR
protocol.
All primers were synthesized by Integrated DNA Technologies (Coralville, IA). The
primer sequences were determined using Primer 3 software (developed by Steve Rozen, Helen J.
Skaletsky, 1996, 1997) available at http://www-genome.wi.mit.edu. All primers were selected
with the following parameters: length 20-22 bases; Tm 57 and 65°C, optimal Tm 60-62°C;
amplification product length 200-500 bp. When possible, the primers were selected to span
different exons, so that the amplification product obtained from cDNA would be of different
length from that obtained from any contaminant genomic DNA. Sequence specificity was
confirmed using Genbank Blast at the National Center for Biotechnology Information website
(www.ncbi.nlm.nih.gov). The following primers were used: Runx2 forward 5′CCAAATTTGCCTAACCAGAATG-3′; Runx2 reverse 5′-GAGGCTGTGGTTTCAAAGCA-3′;
CollagenI forward 5′-GAGCTGGTGTAATGGGTCCT-3’; Collagen 1 reverse 5′GAGACCCAGGAAGACCTCTG-3; ALP forward 5’-GCCCTCTCCAAGACATATA-3’; ALP
reverse 5’-CCATGATCACGTCGATATCC-3’; OPG forward 5’ATCAGAGCCTCATCACCTT-3’; OPG reverse 5’-CTTAGGTCCAACTACAGAGGAAC-3’.
Results were expressed as the ratio of the target gene transcript to the reference gene transcript
(GAPDH; forward 5’-CTCACTGGCATGGCCTTCCG-3’; reverse 5’ACCACCCTGTTGCTGTAGCC-3’).
PCR products were resolved on 1.5 % agarose gels in 1X TBE impregnated with
ethidium bromide. A 1 kb DNA ladder (ThermoFisher, Waltham, MA) was run on each gel to
confirm the expected length of amplification products. Digital images of the ethidium bromidestained agarose gels were acquired using a Fujifilm Fla-4000 imager and the band intensities
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were determined using ImageJ software (NIH, Bethesda, MD and expressed as relative
absorbance units. Each primer product was normalized to the intensity of bands produced with
GAPDH primers for each RNA sample.
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Results
CB2 gene deletion increases atherosclerotic plaque calcification
The presence of calcium deposits in atherosclerotic lesions is a well-known risk factor for
adverse cardiovascular events. We assessed the degree of calcium deposition in lesions of CB2+/+
and CB2-/- mice after 20 weeks of atherogenic diet by staining aortic root cross sections using the
von Kossa method (Figure 3.1). We observed that calcium deposits were mainly present on the
lumenal side of the intima, as expected, coincident with increased presence of VSMCs in this
area (data not shown). Digital quantification of the area staining positive for calcium revealed
~2.3 fold more calcification present in lesions of CB2-/- mice compared to CB2+/+ mice (13.0±1.1
versus 5.6±1.2%, respectively; p=0.002). Similar results were obtained when we stained aortic
root cross sections for calcium deposition using another calcium stain, Alizarin red S (data not
shown).
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Figure 3.1 CB2 gene deletion increases calcium deposition in atherosclerotic lesions of Ldlr-null
mice. A) Representative photomicrographs of von Kossa stained aortic root cross sections from
CB2+/+ and CB2-/- mice fed an atherogenic diet for 20 weeks. B) Quantification of calcium
deposition within aortic root lesions of CB2+/+ and CB2-/- mice. Data is represented as the
percent of positive stain area per total lesion area. *p<0.05. Data is the mean (n=8) ±S.D.

CB2 deletion reduces osteoclast activity in advanced atherosclerotic lesions
Mineralization can occur as a result of an imbalance between osteoblasts, bone-forming
cells, and osteoclasts, bone-resorbing cells. Active osteoblasts demonstrate alkaline phosphatase
(ALP) activity. We stained aortic root cross sections for ALP activity using BCIP/NBT substrate
and found no significant difference in ALP activity in lesions of CB2+/+ and CB2-/- mice fed an
atherogenic diet for 20 weeks (Supplemental Figure 3.5). We next evaluated osteoclast activity
in the aortic root lesions by staining for tartrate-resistant acid phosphatase (TRAP) activity
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(Figure 3.2a). TRAP-positive staining was mostly present in the shoulder regions of the aortic
root lesions and was significantly increased (~2.2 fold) in CB2+/+ mice compared to CB2-/- mice
(9.7±0.05 versus 4.9±0.16%, respectively; p=0.02). Since osteoclast formation is centrally
regulated by RANKL, and osteoblast production of RANKL induces osteoclastic differentiation
and maturation of osteoclast precursors (Walsh and Choi, 2003), the levels of RANKL present in
aortic root lesions was evaluated by immunofluorescence using an antibody to soluble RANKL.
The majority of RANKL immunofluorescence was observed in the shoulder regions of the
lesions (Figure 3.2c), in the same regions showing TRAP activity. Digital quantitation of the
fluorescent intensity found significantly more RANKL staining in aortic root lesions of CB2+/+
mice compared to CB2-/- mice (0.2±0.0004 versus 0.04±0.0040, respectively; p<0.001).
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Figure 3.2 CB2 deficiency reduces TRAP activity within atherosclerotic lesions of Ldlr-null
mice. A) Representative photomicrographs showing TRAP activity (pink) in aortic root lesions
of CB2+/+ and CB2-/- mice fed an atherogenic diet for 20 weeks. B) Representative fluorescent
micrographs of sRANKL immunoreactivity in aortic root lesions in CB2+/+ and CB2-/- mice. C)
Quantification of TRAP activity within aortic root lesions. Data is represented as percentage of
positive stain per total lesion area. D) Quantification of sRANKL immunoreactivity within the
aortic root lesions. Data is represented as the mean ±S.D. of the ratio of FITC signal intensity
relative to DAPI signal intensity. n=6. *p<0.05; **p<0.001.
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CB2 gene deletion alters aortic levels of key osteogenic proteins, Runx2, OPN and OCN
We next used immunoblotting to examine aortic levels of three factors (Runx2, OPN, and
OCN) known to be important for vascular calcification (Figure 3.3). Runx2 is a master
transcriptional regulator of osteoblastogenesis, and its expression functions in both a positive and
negative fashion during the maturation of osteoblast precursors into calcifying cells (Bruderer et
al., 2014). SMC-specific deletion of Runx2 greatly reduces medial and HFD-induced vascular
calcification in mice (Sun et al., 2012; Lin et al., 2015). OPN is biologically diverse but in the
setting of biomineralization it specifically functions as a potent inhibitor of ectopic vascular
calcification (Lund et al., 2009). OCN, on the other hand, is secreted by mature osteoblasts and is
a positive regulator in calcification (Sila-Asna et al., 2007). Aortas of CB2+/+ mice contained
dramatically greater amounts of Runx2 (~2.5 fold, p=0.03) and OPN (~3.7 fold, p=0.02)
compared to aortas of CB2-/- after 20 weeks of HFD. In contrast, the level of OCN in aortas of
CB2+/+ mice was reduced compared that of aortas from CB2-/- mice, although the difference did
not reach statistical significance.
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Figure 3.3 CB2 deficiency alters protein expression of osteogenic regulatory proteins in Ldlr-null
mice. Immunoblot showing levels of Runx2 (A), OCN and OPN (B) in aorta from three CB2+/+
and three CB2-/- mice after 20 weeks of HFD. C) Quantification of Runx2, OCN, and OPN levels
relative to the housekeeping protein, HSC70. Data are means±S.D. (n=3) for each genotype.
*p<0.05. n.s. = not significant

CB2 gene deletion alters osteoblast gene expression
In addition to Runx2, OPN, and OCN, which have been demonstrated to play a role in
vascular calcification in animal models, other osteoblast-specific genes implicated in soft tissue
mineralization, as well as normal bone formation, may also be modulated by CB2 in vascular
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tissue (Sage et al., 2010). Total aortic mRNA for Runx2, Collagen 1 (Col1), ALP, and
osteoprotegerin (OPG) was analyzed by semiquantitative RT-PCR to further assess differences
in relative mRNA expression of osteogenic genes between CB2+/+ mice and CB2-/- mice (Figure
3.4). After normalizing to GAPDH expression levels, we found that after 20 weeks of
atherogenic diet, CB2-/- mice had significantly (p<0.05) greater relative mRNA expression of
Runx2 (~1.6 fold), ALP (~4.8 fold), ColI (~1.7 fold) and OPG (~1.3 fold) compared to CB2+/+
mice.
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Figure 3.4 CB2 deficiency alters the relative levels of mRNA for osteogenic genes in Ldlr-null
mice. A) Semiquantitative RT-PCR of Runx2, ColI, ALP, and OPG expression in aortas from
CB2+/+ and CB2-/- mice (n=3 for each genotype) fed an atherogenic diet for 20 weeks. RT-PCR
of mRNA levels in aortas of chow fed CB2+/+ and CB2-/- mice is shown for comparison. B)
Quantification of Runx2, ColI, ALP, OPG gene expression in CB2+/+ and CB2-/- mice. Bar
graphs represent the mean ± S.D. relative levels for each target mRNA:GAPDH mRNA ratio for
the data shown in panel A. Results shown are from one analysis performed in triplicate and
representative of two independent experiments. *p<0.05.
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Discussion
Many in vivo and in vitro studies have provided evidence of a role for CB2 signaling in
regulating immune processes involved in atherogenesis (Steffens et al., 2005b; Rajesh et al.,
2008; Netherland et al., 2010; Zhao et al., 2010). However, no studies have yet explored the role
of CB2 in atherosclerotic lesion calcification. Mineralization of arterial plaques is a pathological
condition that results in reduced vessel elasticity and increased susceptibility to plaque rupture,
and is associated with increased risk of heart attack (Beadenkopf et al., 1964). In the current
study, we explored the role of CB2 in atherosclerotic mineralization by determining the effects
of systemic CB2 gene deficiency on calcification of advanced lesions in Ldlr-null mice fed an
atherogenic diet. The results of our study show that the absence of CB2 exerts a pro-calcific
effect that enhances mineralization of atherosclerotic lesions.
Calcification of vessels occurs in two distinct locations: the media and the intima. Ectopic
calcification of atherosclerotic plaques in the intimal layer of the vessel is a cell-mediated
process that is modulated by a delicate balance of positive and negative regulators, much like
osteogenic pathways controlling normal bone formation. A regulated balance between osteoblast
and osteoclast is crucial for maintaining bone homeostasis. We found that CB2 deletion resulted
in decreased osteoclast activity, as determined by analysis of TRAP activity, in aortic root
lesions of Ldlr-null mice. RANK/RANKL signaling is necessary for osteoclast maturation and
function. Consistent with decreased osteoclast activity in lesions of CB2-null mice, they also
displayed decreased expression of soluble RANKL. In addition, osteoclastogenesis is restrained
in tissues expressing OPG, a soluble decoy receptor for RANKL, and mRNA levels of OPG
were found to be significantly elevated in atherosclerotic aortas of CB2-null mice. Together,
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these observations suggest that CB2 deficiency enhances lesion calcification, in part, by reducing
osteoclast-like activity in lesions.
VSMCs play an important role in plaque calcification, as they adopt an osteoblast-like
phenotype through a process of osteoblastic transdifferentiation that is regulated by a network of
transcription factors and bone matrix proteins (Shanahan et al., 1993; 1999; Tyson et al., 2003).
Runx2 is a master transcriptional regulator of osteoblast gene expression and osteoblastogenesis,
exhibiting a stage-dependent positive and negative role in osteoblast maturation. Inactivation of
the Runx2 gene results in unmineralized skeletons in mice (Ducy et al., 1997) and SMC-specific
deletion of Runx2 in ApoE-null mice reduces formation of osteoblast-like cells and calcium
deposition in atherosclerotic lesions (Sun et al., 2012; Lin et al., 2015). Although the
commitment of precursor cells to the osteoblast lineage is dependent upon Runx2 expression,
expression of Runx2 beyond early commitment is detrimental and diminishes the capability of
pre-osteoblasts to mature into functional osteoblasts (Bruderer et al., 2014). Here we observed
that enhanced lesion calcification in the setting of CB2 deficiency was associated with decreased
Runx2 protein levels and slightly increased Runx2 mRNA levels in atherosclerotic aortas.
Several studies have reported a similar discordance between Runx2 mRNA and protein levels,
concluding that Runx2 expression is regulated at the post-translational level (Prince et al., 2001;
Sudhakar et al., 2001). Osteoblast differentiation is also negatively regulated by ubiquitinmediated degradation of Runx2 (Shen et al., 2006; Jonason et al., 2009). Together, our results are
consistent with CB2 exerting anti-calcifying effects in lesions, in part, by inhibiting Runx2
degradation and restraining the maturation of pre-osteoblasts. Recent studies indicate that
phosphorylation, acetylation, SUMOylation and ubiquitination regulate Runx2 functions
differently (Wee et al., 2002; Qiao et al., 2006; Shen et al., 2006; Huang et al., 2012) and the
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effects of CB2 signaling on post-translational regulation of Runx2 functions are currently
unknown and merit further investigation.
An ECM containing an abundance of type I collagen is necessary for osteoblast
differentiation and expression of osteoblast-related genes (Franceschi, 1999). These genes, which
encode for proteins such as OCN and ALP, are necessary for mineralization (Murshed et al.,
2005). We found a significant increase of ALP and ColI mRNA in atherosclerotic aortas of CB2null mice, accompanied with an increase in OCN protein expression. While ALP mRNA levels
are upregulated in CB2-deficient mice, biochemical staining failed to detect enhanced ALP
activity in CB2-deficient lesions. Future studies utilizing immunoblotting and
immunohistochemical analysis are needed to clarify the effect of CB2 deficiency on ALP
expression in lesions.
In addition to regulating the expression of several osteoblast marker genes, Runx2 also
regulates the expression of OPN in non-osteoblastic cells (Ducy et al., 1997), such as
macrophages. OPN regulates mineralization by acting as a potent inhibitor of vascular
calcification (Wada et al., 1999; Lund et al., 2009) and is also crucial for normal bone resorption
through its role in osteoclast migration and differentiation (Chellaiah et al., 2003). Here we
found a significant decrease in OPN protein expression in lysates of atherosclerotic aortas from
CB2-deficient mice. This observation suggests that CB2 may exert anti-calcifying effects by
elevating OPN levels in lesions.
In summary, the current study provides the first evidence for a role of CB2 in
calcification of atherosclerotic lesions in a murine model of atherosclerosis. While more studies
need to be done in order to further delineate the mechanisms by which CB2 signaling alters
plaque calcification, our data indicates that CB2 reduces calcification, at least partially, through
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down-regulation of osteoblastic gene expression and upregulation of osteoclast activity. These
results provide a foundation for potential CB2-directed drug development that can help to reduce
or slow calcification of plaques, thereby reducing the morbidity and mortality associated with
advanced disease progression.
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Supplemental Figure 3.5 CB2 deficiency does not affect ALP activity within atherosclerotic
lesions of Ldlr-null mice. A) Representative photomicrographs showing ALP activity (pink) in
aortic root lesions of CB2+/+ and CB2-/- mice fed an atherogenic diet for 20 weeks. B)
Quantification of ALP activity within aortic root lesions. Data is represented as percentage of
positive stain per total lesion area and mean±S.D. n=6 for each group.
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Abstract

Objective: Atherosclerotic calcification is a risk factor for future adverse cardiovascular events.
Cannabinoid receptor type 2 (CB2) activation reduces plaque burden in murine models of
atherosclerosis. CB2 is well known to modulate bone remodeling processes and we recently
observed that CB2 deficiency in Ldlr-null mice enhances lesion calcification. However, the
ability to affect atherosclerotic calcification by pharmacologically targeting CB2 is unknown.
Therefore, we investigated the effects of JWH-015 (CB2-selective agonist) and SR144528 (CB2seelctive inverse agonist/antagonist) on calcification of atherosclerotic lesions in hyperlipidemic
low-density lipoprotein receptor (Ldlr) null mice.
Methods and results: At 8 weeks of age, Ldlr-null mice were placed on a high fat diet (HFD) for
24 weeks with administration of either JWH-015 (1mg/kg) or SR144528 (1mg/kg) three times a
week for the final four weeks. No change was observed in mean body mass or total plasma
cholesterol in response to either treatment; however, total plasma triglycerides were significantly
decreased in CB2+/+ mice in response to SR144528 administration (116.7±13.3 versus
292.1±37.1 mg/dL; p=0.0009). Aortic root lesion area was not discernably affected by treatment
with either JWH-015 or SR144528. Von kossa staining of aortic root lesions revealed Ldlr-null
mice treated with SR144528 had significantly less calcium deposition compared to controls
(12.7±0.9 versus 15.8±0.7%; p=0.03). Treatment with JWH-015 also reduced calcium deposition
in Ldlr-null mice, but the decrease was not significant. Immunoblot analysis revealed increased
Runx2 and osteopontin (OPN) expression in aortic arch lysates of Ldlr-null mice treated with
JWH-015. Analysis of aortas cultured ex vivo in an osteogenic media revealed that
supplementation of the media with a CB2 agonist decreased aortic calcification while
supplementation with a CB2 antagonist increased aortic calcium deposition.
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Conclusion: Pharmacological targeting of CB2 does not alter lesion size in more advanced
atherosclerotic lesions of Ldlr-null mice, but does affect circulating triglycerides levels and
osteogenic processes in vascular and lesional calcification. This data provides the proof of
principle that CB2-specific therapies might be developed to exert beneficial effects on vascular
and atherosclerotic calcification.
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Introduction

Myocardial infarction and stroke, acute clinical consequences of atherosclerosis, remains
to be the leading causes of morbidity and mortality in the developed world (Benjamin et al.,
2017). Decades of research has provided insight into the mechanisms involved in atherogenesis,
a disease that was once thought to be simply caused by a dysregulation of lipid metabolism.
Atherosclerosis is now recognized as a progressive inflammatory condition of medium- and
large-sized arteries (Libby et al., 2002) involving a complex network of immune cells, lipids, and
other cellular debris over the course of several decades. Currently, the most wildly used therapies
for patients with atherosclerosis are drugs that target hypercholesterolemia (statins) and
hypertension (beta-blockers), two cardiovascular disease risk factors. While these therapies have
been successful in reducing the severity of risk factors in affected patients, they have only
slightly decreased mortality rates associated with heart disease. It is therefore extremely
important for new treatment regimens to be uncovered, and much interest has been gained in
targeting the immune system as a therapeutic approach in an attempt to further decrease
mortality rates associated with atherosclerosis.
Endocannabinoids and other cannabinoids exert the majority of their effects through
binding two G-protein coupled receptors, cannabinoid receptor type 1 (CB1) and cannabinoid
receptor type 2 (CB2). Exogenous cannabinoids such as delta9-tetrahydrocannabinol (THC) are
well-known for their psychotropic effects, and increasing knowledge is being obtained regarding
their anti-inflammatory and immunosuppressive effects. Expression of CB1 is primarily seen in
the central nervous system where its activation results in psychotropic effects, but is also found
in the heart (Bátkai et al., 2004), liver (Osei-Hyiaman et al., 2005), adipocytes (Cota et al.,
2003), and vasculature (Liu et al., 2000). Immunosuppressive effects of cannabinoids are
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mediated through CB2, which is prominently expressed by cells of the peripheral immune
system, but also found on adipocytes (Roche et al., 2006), endothelial cells (Blázquez et al.,
2003; Rajesh et al., 2007), and in the pancreas (Juan-Picó et al., 2006).
Research over the past 15 years has provided evidence for a beneficial role of
cannabinoids in the treatment of inflammatory disorders (Di Marzo et al., 2004; Klein, 2005;
Steffens et al., 2005a; Pacher et al., 2006; Mach and Steffens, 2008; Netherland et al., 2010;
Zhao et al., 2010a; 2010b; Hoyer et al., 2011). Use of cannabinoid agonists have shown
beneficial CB2-dependent effects in animal models of gastrointestinal diseases (Wright et al.,
2008; Storr et al., 2009), cardiac and hepatic ischemia-reperfusion (Bátkai et al., 2007; Defer et
al., 2009), and various neurological disorders (Malan et al., 2001; Klegeris et al., 2003). In the
setting of atherosclerosis, the role of CB2 is not completely understood, although there is strong
evidence for an atheroprotective function. Reduction of atherosclerosis has been shown in ApoEnull mice after administration of plant-derived (THC) (Steffens et al., 2005a) and synthetic
(Win55,212-2) (Zhao et al., 2010b) cannabinoids. These effects were attributed to decreased
adhesion molecule activation and monocyte recruitment, and were abolished in the presence of
CB2, but not CB1, antagonists. A study from our laboratory using WIN55,212-2 in Ldlr-null
mice did not find CB2-dependent effects on lesional macrophage infiltration, but did find
reductions in lesional smooth muscle cell (SMC) content and apoptosis (Netherland-Van Dyke et
al., 2015a). In another study, we observed increased lesional macrophage infiltration in Ldlr-/mice lacking CB2 (Netherland et al., 2010). Other independent investigators have also reported
systemic and hematopoietic-specific CB2 gene deletion increases macrophage content in
atherosclerotic lesions from Ldlr-null (Delsing et al., 2011; Willecke et al., 2011) and ApoE-null
mice (Hoyer et al., 2011). Yet, other investigators have reported seemingly conflicting results of
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the effects of the synthetic CB2 agonist JWH-133, with lesion progression being either
unaffected in Ldlr-null mice (Willecke et al., 2011) or reduced in ApoE-null mice (Hoyer et al.,
2011). The variability in these results, possibly due to strain-specific differences in the
atherosclerosis mouse models (Ldlr-/- vs ApoE-/-) and differences in the chemical composition of
synthetic drugs, has made it difficult to uncover a consensus view of the therapeutic potential for
CB2 in the progression of atherosclerosis.
Calcification of advanced atherosclerotic plaques is a risk factor for adverse
cardiovascular events, independent of traditional risk factors such as smoking, diabetes, obesity,
and physical inactivity. Recently, we found that CB2 gene deficiency increases plaque
calcification in Ldlr-null mice fed an atherogenic diet for 20 weeks (manuscript in preparation).
In this study, we investigated the effects of pharmacologically targeting CB2 with an agonist and
an antagonist on atherosclerotic calcification in Ldlr-null mice in vivo and in aortas cultured in
an ex vivo model of vascular calcification.
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Materials and Methods

Animal atherosclerosis and pharmacological administration protocol
Ldlr-null mice (CB2+/+) and Ldlr-null mice lacking CB2 (CB2-/-) were as previously
described (Netherland et al., 2010). At 8 weeks of age, groups (n=8) of male mice were placed
on an high fat diet (HFD) consisting of 21% fat and 0.15% cholesterol (Harlan Teklad, Madison,
WI) for a total of 24 weeks. During the final 4 weeks of HFD feeding, groups of mice received
intraperitoneal (i.p.) injections of either 1mg/kg JWH-015 (Tocris, Bristol, United Kingdom) or
1mg/kg SR144528 (Tocris, Bristol, United Kingdom) diluted in 50% DMSO/50% saline three
times per week (Monday, Wednesday, Friday). Control mice received i.p. injections of an
equivalent volume of vehicle (100 µL).
All mice were housed in a pathogen-free, temperature- and humidity-controlled room in the
Animal Research Facility at East Tennessee State University. Mice were maintained on a
standard chow diet (Ralston Purina, St. Louis, MO) with water provided ad libitum. All animal
procedures were approved by and conducted in accordance with the guidelines administered by
the Institutional Animal Care and Usage Committee of East Tennessee State University and in
conformity with the Public Health Service Policy on Humane Care and Use of Laboratory
Animals published by the National Institutes of Health.

Physiological Parameters
Following an overnight fast, blood samples were collected under anesthesia by cardiac
puncture. Blood was separated by centrifugation and plasma was assayed for total cholesterol
and triglyceride levels using commercially available kits (Pointe Scientific, Inc., Canton, MI)
according to manufacturer’s protocol.
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Analysis of Atherosclerosis
Anesthetized mice were euthanized as previously described (Netherland et al., 2010) and
hearts containing proximal aortic arch and brachiocephalic arteries were dissected and snap
frozen in OCT embedding medium. Serial 8µm cross-sections of the aortic root were collected as
previously described (Liu et al., 2005; Netherland et al., 2010). The extent of atherosclerosis was
determined by computer-assisted morphometric analysis using ImageJ (NIH, Bethesda, MD)
following oil-red O staining for neutral lipid content as previously described.

Histological Staining
Calcium deposition was determined using the von Kossa method. Positive staining areas
were quantified using NIH ImageJ software and represented as the percentage of total
atherosclerotic plaque area relative to control. For each sample, a minimum of four slides
containing four cross sections were evaluated and averaged.

Immunoblotting
Atherosclerotic aortas (aortic arch and thoracic aorta) were homogenized in 1X cell lysis
buffer (Cell Signaling Technology, Danvers, MA) supplemented with 1X protease inhibitor mix
(Sigma-Aldrich, St. Louis, MO). Protein content was determined using a microBCA kit (Thermo
Scientific, Waltham, MA). Lysates containing 20µg of protein were separated on 4-12% Bis/Tris
gels (Invitrogen, Carlsbad, CA) and transferred to a polyvinylidene fluoride membrane.
Membranes were blocked for 1h at room temperature in tris-buffered saline 0.1% tween 20
(TBS-T) containing 5% non-fat dry milk and probed with antibodies to Runx2 (Santa Cruz,
Dallas, TX; sc-10758) (1:2000 dilution) and OPN (R&D Systems, Minneapolis, MN; AF808)
(1:3000) overnight at 4ºC. Membranes were washed with TBS-T and incubated with either goat
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anti-rabbit (1:2000 dilution, for Runx2) or rabbit anti-goat (1:2000, for OPN) horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz, Dallas, TX) and developed using
Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Bio-Sciences,
Pittsburgh, PA) and a Fujifilm Fla-4000 imager. Membranes were stripped and probed with a βactin antibody (Neomarkers, Portsmouth, NH; RB-9421-PO) (1:3000) to serve as a loading
control.

Ex vivo organ culture
Thoracic aortas were dissected from CB2+/+ mice maintained on a standard chow diet and
cultured in DMEM supplemented with 15% fetal bovine serum, 100 U/mL penicillin, and 100
mg/mL streptomycin at 37ºC in a humidified atmosphere containing 5% CO2. Induction of
calcification was achieved by addition of 2.6 mmol/L Pi (Na2HPO4/NaH2PO4, pH 7.4) to the
culture medium (osteogenic media). Aortas were treated with either CB2 agonist HU-308
(Cayman Chemical, Ann Arbor, MI) or CB2 antagonist SR144528 (Tocris, Bristol, United
Kingdom) in osteogenic media at a final concentration of 2 µM. Segments of the same aorta
were placed in separate culture wells, with one segment incubated with osteogenic media alone
(control) and the other segments cultured in osteogenic media supplemented with either HU-308
or SR144528. At the end of 4 days, the segments were washed with phosphate buffered saline
and snap frozen in OCT medium and cryosectioned at 8 µm. Calcium deposition was visualized
by staining of thawed cryosections with 2% Alizarin red (pH 4.2) for 5 min followed by rinsing
with dH2O three times. Digital images were acquired and the extent of calcium deposition was
determined by quantifying the Alizarin red stained area by computer assisted morphometric
analysis with ImageJ software (NIH, Bethesda, MD).
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Statistical Analysis
Data are presented as means±S.D. Student’s t-test or ANOVA methods were employed
using SigmaPlot (StyStat Software, Chicago, IL) to assess differences between groups, with
probability values of less than 0.05 considered statistically significant.

Properties of all synthetic cannabinoids used in this study are listed in the supplemental (SF 4.6).
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Results

SR144528 decrease plasma triglyceride levels in Ldlr-null mice
Ldlr-null mice with and without CB2 (CB2+/+ and CB2-/-, respectively) were fed an
atherogenic diet for 24 weeks to induce the formation advanced atherosclerosis. During the last 4
weeks, groups of mice we given i.p. injections of either JWH-015 or SR144528 at a final
concentration of 1mg/kg three times per week. Control mice were given the same volume of
vehicle. After treatment with exogenous CB2 ligands, no significant differences in mean body
mass (Figure 4.1a) or plasma cholesterol (Figure 4.1b) were observed for either genotype.
Although plasma triglyceride levels tended to be lower in CB2-/- mice compared to CB2+/+ mice,
the difference did not reach statistical significance (Figure 4.1c). Treatment of CB2+/+ mice with
SR144528 resulted in a ~60% decrease in plasma triglyceride levels compared to controls
(116.7±13.3 versus 292.1±37.1 mg/dL, respectively; p=0.0009), an effect which was absent in
CB2-/- mice (264.4±31.8 versus 191.7±33.1 mg/dL, respectively; p=0.1). Treatment with either
JWH-015 or SR144528 did not affect the size of established aortic root lesions in either genotype
(Figure 4.1d).
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Figure 4.1 SR144528 reduces triglyceride levels in Ldlr-null mice by a CB2-dependent
mechanism. Body weights (A) serum cholesterol (B) triglyceride (C) and aortic root lesion size
(D) of CB2+/+ and CB2-/- mice after 24 weeks of HFD in which the mice were given i.p.
injections of JWH-015 or SR144528 (1mg/kg, 3x per week) for the final 4 weeks. The results are
the mean±S.D. (n=6-8). *p<0.001

SR144528 treatment reduces calcium deposition in atherosclerotic plaques
We next compared the extent of atherosclerotic calcification in Ldlr-null (CB2+/+) mice
treated with JWH-015 or SR144528 by von Kossa staining aortic root cross sections (Figure 4.2).
Quantification of the lesion area staining positive for calcium revealed that treatment with the
CB2 agonist, JWH-015, reduced the calcium deposition compared to controls, but the decrease
did not reach statistical significance. Surprisingly, treatment with the CB2 antagonist,
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SR1144528, also resulted in less calcium deposition (12.7±0.9 versus 15.8±0.7% for controls;
p=0.03). Treatment with either compound did not significantly affect the extent of calcium
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deposition in aortic root lesions of CB2-/- Ldlr-null mice (see supplemental Table 4.1).
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Figure 4.2 CB2 antagonism reduces atherosclerotic calcification in Ldlr-null mice. A)
Representative photomicrographs of von Kossa stained aortic root cross sections from Ldlr-null
mice following treatment with JWH-015 or SR144528. B) Quantification of total aortic root
lesion area occupied by calcium as indicated by positive von Kossa-staining. Data represented as
relative staining compared to control (vehicle). The results are the mean±S.D. (n=8) *p<0.05.

We previously observed CB2-dependent effects on lesional osteoclast activity (Figure 3.2).
Biochemical staining of tartrate-resistant phosphatase (TRAP) activity in aortic root lesions of
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JWH-015 or SR144528 treated Ldlr-null mice revealed no differences in osteoclast activity from
that in vehicle treated controls (Figure 4.3).
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Figure 4.3 Administration of a CB2 agonist and antagonist does not affect TRAP activity in Ldlrnull mice. A) Representative photomicrographs of aortic root cross sections stained for TRAP
activity from CB2+/+ mice after 24 weeks of HFD with i.p. injections of either JWH-015 or
SR144528 over the final 4 weeks. B) Quantification of percent of total lesion area staining
positive for TRAP activity. Data is presented as the mean±S.D. (n=8)
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Administration of exogenous ligands alters aortic Runx2 and OPN protein levels in Ldlr-null
mice

Runx2 is a master transcription factor controlling osteoblastogenesis in a stage-dependent
manner (Bruderer et al., 2014). At early stages of development, Runx2 functions in the
commitment of precursor cells to the osteoblast lineage; however, Runx2 inhibits the maturation
of pre-osteoblasts in later stages. We previously found that Runx2 was decreased in calcified
aortic lesions of CB2-/- mice compared to CB2+/+ mice (Figure 3.3). Further, in early
atherosclerotic lesions of Ldlr-null mice fed HFD for 12 weeks, treatment with WIN55,212-2, a
mixed CB1/CB2 agonist, increased aortic expression of Runx2 in a dose-dependent manner
(Supplemental Fig. 4.7). Therefore, we determined if the treatment of Ldlr-null mice with JWH015 and SR144528 also affected the level of Runx2 detected in calcified aortic tissues (Figure
4.4a,b). Immunoblot analysis using showed no discernable differences between the amount of
Runx2 in aortas from SR144528-treated mice and vehicle control mice. However, Runx2 levels
were significantly elevated in calcified aortas from JWH-015-treated mice compared to the
vehicle control.
Osteopontin (OPN) is an important regulator of osteogenesis, as it serves as a potent
negative regulator of ectopic mineralization in vascular tissue (Scatena et al., 2007). In early
atherosclerotic lesions of Ldlr-null mice fed HFD for 12 weeks, administration of WIN55,212-2
dose-dependently increases in aortic OPN expression (Supplemental Fig. 4.7). Immunoblot
analysis showed greater OPN levels in aortas of JWH-015-treated Ldlr-null mice and decreased
levels in aortas of SR144528-treated mice compared to control mice (Supplemental Figure 4.8).
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Figure 4.4 Upregulation of Runx2 levels in calcified aortas of Ldlr-null mice treated with JWH015. Immunoblot analysis of aortic arch lysates from Ldlr-null mice after 24 weeks of HFD and
4 weeks of i.p. administration of JWH-015 or SR144528. A) Representative immunoblot of
aortic tissue probed with Runx2 antibody. B) Quantification of Runx2 protein levels detected by
immunoblotting of aortic arch lysate. Data is presented as the mean±SD ratio of the intensity of
the target protein relative to a loading control protein (HSC70). (n=3) *p<0.05.

Administration of exogenous ligands alters vascular calcification in ex vivo cultured aortas

To more rapidly screen exogenous CB2 ligands for effects on vascular calcification we
utilized a recently developed culture method of inducing calcification of aortas ex vivo (Akiyoshi
et al., 2016). This method uses an osteogenic media containing 2.6 mM Pi to induce aortic
calcification in 3-5 days of culture (Akiyoshi et al., 2016). Each aorta dissected from an Ldlr-
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null mouse fed a normal chow diet was cut in half, with one half cultured in osteogenic media
(OG) and the other half cultured in OG media supplemented with a CB2 agonist (HU-308) or
OG media supplemented with a CB2 antagonist (SR144528) (Figure 4.5a). After 4 days in
culture, the aortas were removed and adjacent 8 µm cryosections were prepared for analysis of
calcium deposition by staining with alizarin red (Figure 4.5b). Calcium deposition in aorta
segments cultured in the presence of HU-308 was reduced compared to that seen in the
corresponding segments cultured in OG media alone, while aorta segments cultured in the
presence of SR144528 had increased calcium deposition relative to their corresponding control
aorta segments (Figure 4.5c). Aorta segments cultured in standard media (0.9 mM Pi) did not
show positive staining with alizarin red (data not shown).
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Figure 4.5 CB2 agonist and antagonist differentially affect calcification of aortas ex vivo. A)
Schematic of culture method. B) Representative photomicrographs of alizarin red stained cross
sections of aorta segments after culture in osteogenic medium (control), and osteogenic medium
containing either 2µM HU-308 or 2µM SR144528 for 4 days. B) Quantification of the effect of
HU308 and SR144528 on calcium deposition in aorta segments from 6 different Ldlr-null mice.
Data is presented and the mean±S.D. of the ratio of the % area staining positive for the treatment
and the % area staining positive in the corresponding control aorta segment from the same
mouse. A total of four sections were stained for each segment and averaged. *p<0.05
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Discussion

Previous studies have provided evidence supporting a CB2-dependent reduction in early
atherosclerosis progression in atherogenic ApoE-null mice treated with synthetic cannabinoids
WIN55,212-2 (Zhao et al., 2010a; 2010b) and JWH-133 (Hoyer et al., 2011). Further, CB2dependent and –independent roles were observed in Ldlr-null mice treated with WIN55,212-2
after initiation of early atherosclerotic lesions (Netherland-Van Dyke et al., 2015a). These
studies assessed CB2-dependent characteristics such as lesion size and monocyte
entry/macrophage content, but with some contradicting results. For instance, administration of
natural or synthetic CB1/CB2 agonists in ApoE-null mice demonstrates atherosclerotic lesion
size regression in a CB2-dependent manner (Steffens et al., 2005b; Zhao et al., 2010a; 2010b;
Hoyer et al., 2011); however, this drug-induced effect on lesion burden has not been observed in
Ldlr-null mice (Delsing et al., 2011; Willecke et al., 2011; Netherland-Van Dyke et al., 2015b).
These apparently contradictory results could be explained, at least in part, by the strain-specific
differences between ApoE- and Ldlr-null mice. In support of this, it is well-known that these two
murine models of atherosclerosis differ in a number of parameters which can affect the
pathophysiological characteristics of atherosclerosis (Daugherty and Rateri).
While increasing evidence has accumulated supporting a role for CB2 in modulation of
early atherogenesis, to date, the effects of synthetic cannabinoids on processes in advanced
atherosclerosis has not yet been explored. Most atherosclerotic plaques remain clinically
insignificant, remaining stable enough to never initiate adverse cardiovascular events. However,
among a significant population of people, unstable plaques become prone to rupture and
subsequent thrombolytic activity creates the potential for myocardial infarction or stroke to
occur. Beyond traditional risk factors, calcification of atherosclerotic plaques is a major risk
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factor for lesion instability and is highly correlated with mortality associated with
atherosclerosis. In the present study, we provide the first evidence of the effects of synthetic
cannabinoid administration on calcification of advanced atherosclerotic plaques in a murine
model of atherosclerosis.
Consistent with our previous studies of CB2 deficiency in Ldlr-null mice, we found no
effect on plaque burden or mean body mass of targeting CB2 in Ldlr-null mice with JWH-015 or
SR144528. We did however, note SR144528 significantly reduced plasma triglyceride levels.
Previously, our laboratory showed a reduction of plasma triglyceride levels associated with
WIN55,212-2 administration in early atherogenesis (Netherland-Van Dyke et al., 2015a), but this
effect was not CB2-dependent and was likely mediated through CB1 which is known to
modulate plasma triglyceride levels in humans (Després et al., 2005; Van Gaal et al., 2005; PiSunyer et al., 2006; Scheen and Van Gaal, 2007) and in mice (Dol-Gleizes et al., 2009). In
another study from our laboratory, we found SR144528 blocked acyl-coenzyme A: cholesterol
acyltransferase (ACAT) activity and lipid accumulation in macrophages (Thewke et al., 2009),
providing evidence for a role of CB2 blockade in lipoprotein metabolism while another group
demonstrated AM1241 resulted in CB2-dependent intracellular lipid accumulation in
hepatocytes in vitro (De Gottardi et al., 2010). These studies provide evidence that CB2dependent mechanisms also affecting lipid metabolism independently from CB1. However, it has
been shown that SR144528 shares structural similarity to CB1 antagonist SR141716A, and it
could be that in the absence of CB2 signaling, CB1 expression in the liver becomes downregulated in the presence of SR144528.
Our observation that blockade of CB2 by SR144528 reduced atherosclerotic lesion
calcification in Ldlr-null mice, was somewhat surprising, as we observed lesion calcification to

131

increase in the setting of systemic CB2 deficiency in Ldlr-null mice. We speculate that this
seemingly CB2-dependent effect might be related to the drastic decrease in plasma triglycerides
elicited by SR144528, and not directly involve modulation of CB2 signaling in osteogenic
processes. Evidence for this is two-fold: first, there is an invariable association between lipids
and deposition of calcium crystals in atherosclerotic plaques (Hirsch et al., 1993; Parhami et al.,
2002; Iyemere et al., 2006; Laird et al., 2006), and second, the expression of Runx2 and OPN in
aorta was not consistent with that expected in an environment of reduced calcium deposition. We
found that activation of CB2 with both WIN55,212-2 and JWH-015 increased Runx2 and OPN
levels in early and late atherogenesis, respectively, which we and others have found to inhibit
maturation of osteoblasts and inhibit calcification (Wada et al., 1999; Prince et al., 2001;
Bruderer et al., 2014; McGee-Lawrence et al., 2014) (unpublished observation, Fulmer ML and
Thewke DP).
To address the effects of pharmacological manipulation of CB2 on vascular calcification
independently of extravascular parameters, such as hepatic triglyceride synthesis, we used an ex
vivo aorta organ culture model. Our preliminary data shows that ex vivo aortas cultured in a high
Pi osteogenic media rapidly induce calcium deposition by mechanism(s) which are inhibited by
CB2 activation and provoked by CB2 antagonism. These results provide additional evidence of
a protective role for CB2 signaling in atherosclerotic calcification and suggest that reduced
atherosclerotic calcification seen in mice treated with SR144528 may be related to off-target or
extravascular effects of SR144528. Further studies are required to determine the mechanism by
which SR144528 reduces lesion calcification.
In conclusion, although administration of CB2-specific ligands does not induce lesion
regression, SR144528 does reduce plasma triglycerides and plaque calcification. CB2 activation
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with JWH-015 alters expression of Runx2 and OPN, key osteogenic regulatory proteins, in Ldlrnull mice. These results demonstrate that CB2 signaling might be a novel target to affect
calcifying mechanisms in later stages of atherosclerotic lesion development, which may
influence lesion stability. Understanding the exact mechanisms by which CB2 signaling directly
and indirectly affects all aspects of lesion development need to be further explored. Many
variable parameters are present in the current study, such as type of synthetic cannabinoid used
as well as initiation, frequency, and duration of dosing. Further studies will need to be done that
addresses these variables in order to provide better insight on how to best target CB2 to achieve
beneficial results.
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Supplemental Figures and Tables

JWH-015
CB2 agonist
Ki= 13.8nM (CB2),
383nM (CB1)

SR144528
CB2 antagonist/inverse agonist
Ki= 0.6nM (CB2),
400nM (CB1)

HU-308
CB2 agonist
Ki= 20nM (CB2),
>10µM (CB1)

Supplemental Figure 4.6 Chemical structures of CB2 agonists and antagonist used in this study.
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Supplemental Figure 4.7 Dose-dependent response of WIN55,212-2 on OPN and Runx2 in aortic
arch lysates. CB2+/+ mice were fed a HFD for 8 weeks, receiving daily i.p. injections of
CB1/CB2 mixed agonist WIN55,212-2 at either 1mg/kg or 3mg/kg in 50%DMSO/50%PBS. A)
Western blot analysis of aortic arch lysates from CB2+/+ mice after 8 weeks of HFD and 2 weeks
of daily i.p. administration of WIN55,212-2. B) Quantification of OPN and Runx2 protein,
expressed as a fold difference over control (50%DMSO/50%PBS).

139

A.

CB2-/-

CB2+/+
JWH-015
SR144528

-

+
-

+

-

+
-

+
OPN
Actin

0.7

B.
OPN/Actin

0.6
0.5
0.4
0.3
0.2
0.1
0.0

vehicle JWH-015 SR144528

Supplemental Figure 4.8 Upregulation of OPN levels in calcified aortas of Ldlr-null mice treated
with JWH-015. Immunoblot analysis of aortic arch lysates CB2+/+ and CB2-/- mice after 24
weeks of HFD and 4 weeks of i.p. administration of JWH-015 or SR144528. A) Representative
immunoblot of aortic tissue probed with OPN antibody. B) Quantification of OPN protein levels
detected by immunoblotting of aortic arch lysate. Data is presented as the ratio of the intensity of
the target protein relative to a loading control protein (Beta actin). n=1.

Analysis of von Kossa staining in aortic root of CB2-/- mice after JWH-015 or SR144528 administration
Treatment
mean±SEM
Probability value versus control
Control (vehicle)
15.8±0.9%
JWH-015
13.4±1.1%
p=0.119
SR144528
17.4±0.9%
p=0.247
Supplemental Table 4.1 Quantification of von Kossa stained aortic root cross sections from CB2/mice after 24 weeks of HFD and 4 weeks of i.p. JWH-015 or SR144528 injections. Data
represented as percent of positive stain per total lesion area.
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CHAPTER 5
CONCLUSIONS
Over the last 15 years, studies involving cannabinoid receptor manipulation has greatly
improved our knowledge surrounding the impact of cannabinoid signaling on atherosclerotic
lesion formation and progression to an advanced disease state. The initial focus of research in
regards to cannabinoid-based therapies for atherosclerosis were centered on actions at CB1,
when the CB1-inverse agonist Rimonabant (SR141716A) was used clinically in Europe as an
anti-obesity therapy and further showed improvements of cardiovascular risk factors which could
not be fully attributed to CB1-mediated weight loss (Després et al. 2005; Poirier et al. 2005; PiSunyer et al. 2006; Scheen and Van Gaal 2007). Beyond its therapeutic potential as a treatment
in the setting of obesity and atherosclerosis, Rimonanbant also produces detrimental
psychological effects through its actions in the CNS. Consequently, Rimonabant was withdrawn
from the European market and never gained approval for use in the U.S. Interest in CB2mediated effects on atherosclerosis came to light in 2005 when Steffens et. al. discovered that
CB2 was expressed in atherogenic vessels, but not in non-diseased areas of vasculature, and that
low-doses of THC could induce plaque regression in a manner that was sensitive to CB2
blockade by SR144528 (Steffens, Veillard, Arnaud, Pelli, Burger, Staub, Zimmer, Frossard, and
Mach 2005b). These initial studies involving CB1 and CB2 provided insight into the opposing
effects of cannabinoid receptor signaling in the face of atherogenesis, and much interest has been
gained in the realm of CB2 due to the lack of psychotropic effects involved in CB2-specific
signaling.
Information gained from the studies described in this dissertation aid in our
comprehension of the role of CB2 in the pathophysiology of atherosclerosis. Specifically, a role
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for CB2 in the modulation of the cellular and extracellular composition of advanced lesions, a
novel avenue explored in the setting of CB2 and atherogenesis. Data uncovered from these
studies indicates a need for future research focused on the identification and development of
CB2-specific ligands and CB2-directed therapies as an interventional approach for
atherosclerosis.
It is well-recognized that cardiovascular disease claims more lives in the developed world
than any other disease, and majority of those affected experience adverse cardiovascular events
that result from complications arising from advanced atherosclerosis (Benjamin et al. 2017).
Atherosclerosis is a decades-long progression of plaque buildup in vessel walls, fueled by
disconcerted inflammatory processes and dysfunctions in lipid homeostasis. Atherosclerotic
lesions can remain virtually asymptomatic for several decades, and in fact, only an estimated 3%
of lesions actually result in acute clinical events (Virmani et al. 2002). Despite this, the need for
intervention of the progression of this disease is not overshadowed by this relatively low statistic,
as complications from this disease still kills thousands of people each year.
In the last 10 years, most initial research on the role of CB2 in atherosclerosis was
focused on the potential for regression of lesion size in the response to CB2 activation. However,
increasing knowledge has emerged indicating a weak correlation between lesion size and
progression to a rupture-prone phenotype. It is now more accepted that alteration in lesion
composition accompanied with disease progression is more prognostic of the transition from a
stable to unstable phenotype. Majority of these alterations in lesion composition are a result of
increased pro-inflammatory signaling, resulting in increased influx of immune cells, defects in
cellular clearance, alterations in extracellular matrix (ECM) composition, and phenotypic
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switching of cell types that bare a high degree of plasticity such as smooth muscle cells (SMCs)
(Finn et al. 2010; Moore and Tabas 2011).
Atherogenesis begins decades before intervention is initiated, often times as early as
childhood. The first histological change in this process that both chemically and microscopically
detectable is the presence of small, isolated groups of macrophages and lipid-laden macrophages,
called “foam cells”, within the human intima. Also termed an “initial lesion” or “fatty streak,”
this initial cellular change is mostly present in children and been found in the coronary arteries of
45% of infants within their first 8 months of life (Stary 1987; Stary 1989). Macrophages develop
from circulating monocytes which migrate to tissues in response to chemoattractant signals and
mature into tissue macrophages where they perform their functions. These cells are versatile
immune cells that serve to phagocytose antigens and other cellular debris and initiate immune
responses by secretion of effector cytokines and presentation of antigens to T lymphocytes, and
are also the predominant cell type found in all stages of atherosclerotic lesion development
(Stary 1992).
Macrophages contribute to the progression of atherosclerosis through propagation of
inflammation and further recruitment of immune cells, making them a potential target for an
anti-inflammatory approach in treatment of atherosclerosis. Administration of natural and
synthetic cannabinoids, THC and WIN55,212-2, has been shown to decrease lesional
macrophage content in ApoE-null mice and inhibit migration and proliferation of macrophages
in vivo and in vitro, by mechanisms sensitive to CB2 blockade (Steffens, Veillard, Arnaud, Pelli,
Burger, Staub, Zimmer, Frossard, and Mach 2005b; Zhao, Y. Liu, et al. 2010; Zhao, Yuan, Y.
Liu, Xue, Tian, W. Liu, W. Zhang, Shen, Xu, Liang, and Chen 2010b). The effects of
WIN55,212-2 administration on macrophage content were two-fold: by limiting monocyte entry

143

into the intima through downregulating endothelial adhesion molecule expression (ICAM-1,
VCAM-1, and p-selectin), and by reducing the inflammatory response through downregulation
of proinflammatory cytokines (Zhao, Y. Liu, et al. 2010; Zhao, Yuan, Y. Liu, Xue, Tian, W. Liu,
W. Zhang, Shen, Xu, Liang, and Chen 2010a). However, definitive conclusions were difficult to
come to in these early pharmacological studies due to the effects of these compounds acting
independently of cannabinoid receptors. THC and WIN55,212-2 both activate PPAR receptors
(O'Sullivan and Kendall 2010) and WIN55,212-2 has been shown to negate IL-1-induced
expression of adhesion molecules independent of cannabinoid receptor signaling (Curran et al.
2005). A role for CB2 in lesional macrophage accumulation was supported in studies utilizing
systemic and bone marrow-derived leukocyte CB2 deficiency in ApoE- and Ldlr-null mice
(Netherland et al. 2010; Delsing et al. 2011; Willecke et al. 2011). However, CB2-dependent
effects of pharmacological manipulation could not be fully appreciated when assessed in a model
containing a functional CB2 receptor. It wasn’t until 2015 that our lab provided the first evidence
of WIN55,212-2 administration reducing lesional macrophage accumulation by a true CB2dependent mechanism (Netherland-Van Dyke et al. 2015). This study also provided evidence of
CB2-independent effects of WIN55,212-2 administration, which is something that should be
considered in pharmacological studies. All of these studies have been performed in models of
atherosclerosis which mimic the initial stages, when pharmacological intervention would not yet
be initiated in human subjects. Here we provide the first evidence of increased macrophage
content in advanced atherosclerotic lesions of Ldlr-null mice lacking CB2 function, suggesting a
role for CB2 throughout many stages of atherogenesis.
As atherosclerotic plaques advance, vascular SMCs (VSMCs) play an important role in
attempting to stabilize the lesion. In response to increased inflammation and a growing necrotic
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core, VSMCs migrate from the media to the luminal side of the intima where they secrete
collagen and other ECM components to form a stabilizing fibrous cap to protect the necrotic core
and prevent prothrombotic components from interacting with the bloodstream (Rudijanto 2007).
The collagen, which makes up over half of the protein content present in atherosclerotic plaques
(Smith 1965), provides strength and stability and is another feature which protects the necrotic
core in lesions which have become moderately advanced (Burleigh et al. 1992; R.T. Lee and
Libby 1997). Thinning of the fibrous cap and proteolytic degradation of collagen and other ECM
components by macrophage-secreted matrix metalloproteinases (MMPs) are processes which can
initiate instability of advanced atherosclerotic lesions (Galis, Muszynski, et al. 1994). Several
MMPs exist, but MMP-9 has been implicated in atherosclerosis and expression of constitutively
active MMP-9 was found to increase plaque fissuring and rupture of lesions in ApoE-null mice
(Gough et al. 2006). Here we provide evidence for a positive role for CB2 in modulating MMP9
expression in advanced plaques, consistent with our previous study performed in early lesions
(Netherland et al. 2010). We also found that fibrous cap thickness was significantly reduced in
the setting of CB2 gene deletion. This suggests that CB2-mediated therapies may be beneficial in
advanced stages for reducing the expression or activity of MMP-9, thereby reducing degradation
of stabilizing ECM components.
Beyond the formation of a fibrous cap, the plasticity of VSMCs contributes to other
processes in advanced lesions which promote an unstable phenotype. VSMCs transdifferentiate
into a synthetic osteoprogenitor cell type where they commit to an osteoblast lineage in the
presence of certain transcription factors and osteogenic regulatory proteins (Steitz et al. 2001).
This process results in ectopic calcification of lesions which augments plaque brittleness and
reduces vessel elasticity (Trion and van der Laarse 2004; Sun et al. 2012) and is a well-known
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major risk factor for adverse cardiovascular events (Detrano et al. 2008; Polonsky et al. 2010).
Here we provide the first evidence for a role of CB2 in calcification of advanced plaques and the
osteogenic processes involved.
Once thought of as a passive process, plaque calcification is now accepted as an active
cellular process similar to normal bone remodeling. Runx2 is a master transcription factor
controlling osteoblastogenesis, bearing both positive and negative regulatory functions. Runx2 is
necessary for commitment of osteochondrocytic precursors to the osteoblast lineage, however, its
expression in subsequent steps of osteoblast maturation are detrimental and blocks the ability of
pre-osteoblasts to become functional, bone-forming cells (Prince et al. 2001; Komori 2009;
Bruderer et al. 2014; Vimalraj et al. 2015). We found that CB2 deficiency resulted in increased
calcification of plaques characterized by decreased expression of Runx2 as well as decreased
expression of OPN, a potent inhibitor of calcification. Regulation of these proteins was also
achieved through pharmacological activation of CB2 at both early and late stages of
atherogenesis. However, pharmacological blockade of CB2 resulted in a slight reduction in
advanced plaque calcification. The inconsistency in this data could be attributed to the marked
reduction of triglycerides also observed in our antagonist-treated mice. It has been well observed
that a uniform association between lipids and calcium crystals exist, and that lipids promote
calcium crystal deposition by stimulating osteogenic differentiation of VSMCs and also by
serving as an independent site of origin for calcification (Hirsch et al. 1993; Parhami et al. 2002;
Laird et al. 2006). Other factors that could affect the results in this study are the concentration
and type of synthetic ligands used as well as the onset, frequency, and duration of treatment. We
utilized an innovative osteogenic ex vivo organ culture method to address the effects of
pharmacological manipulation of CB2 on aortic calcification. Use of this system provides an
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environment more representative of the natural milieu than what is seen in a single cell culture
model and allowed us to assess CB2-dependent effects on vascular calcification that were
independent of extravascular parameters, such as hepatic triglyceride synthesis. We found that
calcium deposition induced by osteogenic media was reduced in the presence of a CB2 agonist
and exacerbated in the presence of a CB2 antagonist. Our data here provides the first evidence of
CB2-mediated effects on osteogenic processes involved in atherosclerotic and vascular
calcification. Further studies need to be employed to address potential off-target or extravascular
effects of CB2 pharmacological manipulation in order to determine if a CB2-mediated therapy
could be beneficial in reducing or slowing down calcification of plaques in an attempt to
stabilize lesions.
Currently, the only approved therapy for atherosclerosis is use of drugs which aim to
reduce serum lipid levels and blood pressure. Reduction of LDL cholesterol with statin therapy
has been the standard treatment since the 1980s (Mozaffarian et al. 2016). However, these drugs
are only shown to reduce the risk of adverse cardiovascular outcomes by 30% (MS et al. 2017).
Further, some patients are intolerant to statins and almost half of patients with normal plasma
lipid levels still develop atherosclerotic plaques (Genest et al. 1991; Rubins et al. 1995; Yusuf et
al. 2016), highlighting the need for new therapies that can be used in the treatment of
atherosclerosis.
Summarized in Figure 5.1, the results presented in this dissertation provide evidence
supporting the potential of CB2 as a novel therapeutic target that could promote lesion stability
by impacting several processes involved in the progression of atherosclerotic lesions to an
unstable phenotype. Future directions include cell-specific CB2 knockdown in both SMCs and
macrophages using adoptive transfer. This will provide further insight into how CB2 signaling
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specifically affects the function of these cells in atherogenesis and lesion stability. Research
efforts aimed at analyzing components of atherosclerotic plaque stability are hindered due to the
inability of mouse models to exhibit true plaque rupture as it occurs in humans. Therefore, it is
hard to make a full comparison of how CB2 signaling regulating these processes in mice will
compare in the setting of human disease. Lesional overexpression of MMP-9 in ApoE-null mice
results in increased intraplaque hemorrhaging and outward remodeling, both signs of plaque
vulnerability (de Nooijer et al. 2006). However, true plaque fissure was not consistently observed
in this model and these findings did not correlate with adverse events seen in humans.
Development of a mouse model which better replicates plaque rupture is needed in order to gain
further insight on the implications of CB2 signaling in these processes.

2-AG

CB2

reduces lesional
macrophages

increases lesional
stability
↓ MMP-9
↑ SMC/macrophage
↑ cap thickness

reduces lesional &
vascular calcification
↑ OPN & Runx2
↓ pro-osteoblastogensis
gene expression
↓ VSMC OBT?

CB2-specific drug therapy could be beneficial in
stabilizing plaques and reducing morbidity/mortality
associated with calcification
Figure 5.1 Summary of dissertation research findings.
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Careful consideration must also be taken when employing cannabinoid-based therapies,
as other pathological conditions have been found to be affected by both CB1 and CB2 signaling.
For instance, we observed a decrease in serum triglycerides in response to SR144528
administration, and previously found that SR144528 blocked ACAT activity and lipid
accumulation in macrophages (Thewke et al. 2009). Increases in intracellular lipid accumulation
in hepatocytes has also been observed in response to CB2-selective agonists (De Gottardi et al.
2010). Therefore, although CB2 activation shows to be atheroprotective in terms of stabilizing
lesions, it may be detrimental in modulating lipid metabolism. Further, cannabinoid receptor
manipulation has also been shown to affect the pathophysiology of other diseases. CB2
activation has been shown to produce anti-inflammatory and immunosuppressive effects in
rheumatoid arthritis, liver cirrhosis, gastrointestinal disorders, and neurodegenerative diseases
(Sumariwalla et al. 2004; Buckley 2008; George et al. 2008; Parker et al. 2008), offering varying
levels of protection in each condition. Studies will need to be done to determine how CB2specific compounds used in the treatment of atherosclerosis may affect the pathology of other
diseases that could result in beneficial and/or adverse effects. The use of tissue-specific drug
intervention may be necessary to avoid any potential complications arising from systemic CB2
activation.
Several CB1/CB2 agonists are used clinically to treat maladies such as side effects
produced by chemotherapy treatment or neuropathic pain. As of 2017, there are 29 states in the
U.S. that have approved the use of cannabis for medical purposes, with each state governing its
regulation independent of another (National Academies of Sciences, Engineering, and Medicine
et al. 2017 Jan 12). The marijuana plant, Cannabis sativa, contains over 700 chemical
compounds, 104 of which are considered to be unique cannabinoids (Mechoulam and Hanuš
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2000; Izzo et al. 2009). The U.S. Food and Drug Administration has not approved marijuana as a
“safe or effective drug for any indication,” but states their awareness regarding research interests
in testing marijuana in the treatment of several medical condition and supports the medical
research community studying the effects of this drug. While marijuana appears to be beneficial
in some disease states, increasing knowledge is being obtained about the adverse cardiovascular
effects of the drug, such as myocardial infarction, cardiomyopathy, stroke, arrhythmias, and
sudden cardiac arrest, all which are mediated through CB1 (Pacher et al. 2017). THC is a partial
agonist at CB1 and likely would not produce harmful cardiovascular effects at lower
concentrations, but over the past 10 years the potency of THC in marijuana has increased 10fold, which has paralleled a substantial rise in severe, and sometimes fatal, adverse
cardiovascular effects. Further, THC is also a partial agonist at CB2 and has been shown to
produce beneficial effects on atherosclerosis when administered at a dose known to be too low to
produce effects at CB1 (Steffens, Veillard, Arnaud, Pelli, Burger, Staub, Zimmer, Frossard, and
Mach 2005a). Therefore, it appears that the composition of the plant has a large effect on the
likelihood of adverse events to occur. Further, poisoning outbreaks and deaths have been on the
rise with the increased use of synthetic cannabinoids, consisting of several CB1 agonists that
have an overall potency of up to 200-times greater than that of THC. These drugs, referred to as
“designer drugs,” have been manufactured to exhibit increased potency over the last 2 years,
coinciding with an increase in fatalities (Banister et al. 2015; Kasper et al. 2015; Law et al. 2015;
Adams et al. 2017).
The rise in adverse effects associated with recreational cannabinoid use has made it
difficult to expand the clinical indication for marijuana or marijuana-based products in the U.S.
The results in this dissertation provide a novel understanding regarding the potential therapeutic
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nature of CB2 signaling in advance atherosclerosis. It further provides a framework for synthetic
cannabinoid administration in advanced disease that serves to stabilize lesions and is devoid of
adverse cardiovascular effects associated with CB1 signaling.
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